WO2022095934A1 - 抗Siglec-15抗体及其在制备药物中的应用 - Google Patents

抗Siglec-15抗体及其在制备药物中的应用 Download PDF

Info

Publication number
WO2022095934A1
WO2022095934A1 PCT/CN2021/128759 CN2021128759W WO2022095934A1 WO 2022095934 A1 WO2022095934 A1 WO 2022095934A1 CN 2021128759 W CN2021128759 W CN 2021128759W WO 2022095934 A1 WO2022095934 A1 WO 2022095934A1
Authority
WO
WIPO (PCT)
Prior art keywords
seq
variable region
chain variable
sequence
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2021/128759
Other languages
English (en)
French (fr)
Inventor
何柯
廖诗骅
冯旭
任宝兰
杜钰涵
陈英娇
宋利平
范艺
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Jmt-Bio Technology Co Ltd
Original Assignee
Shanghai Jmt-Bio Technology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Jmt-Bio Technology Co Ltd filed Critical Shanghai Jmt-Bio Technology Co Ltd
Priority to EP21888626.5A priority Critical patent/EP4242231A4/en
Priority to US18/035,708 priority patent/US20240092897A1/en
Publication of WO2022095934A1 publication Critical patent/WO2022095934A1/zh
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Definitions

  • the present invention relates to the field of biopharmaceuticals, in particular to an anti-Siglec-15 antibody or an antigen-binding fragment thereof, a nucleic acid sequence encoding an anti-Siglec-15 antibody or an antigen-binding fragment thereof of the present invention, an expression vector comprising the nucleic acid sequence, an expression vector comprising the expression A host cell of a vector, a composition comprising an anti-Siglec-15 antibody of the present invention or an antigen-binding fragment thereof, a bispecific antibody or an immunoconjugate of an anti-Siglec-15 antibody of the present invention or an antigen-binding fragment thereof linked to a therapeutic agent, and the present
  • the invention discloses the use of Siglec-15 antibody or its antigen-binding fragment in the preparation of a medicament for treating cancer.
  • Cancer has become an important killer of human health. Due to the aging of the population, the intensification of industrialization, the intensification of urbanization, and the change of lifestyle, the incidence and death of cancer in China continue to increase, and the burden of cancer cannot be ignored.
  • the occurrence and development of cancer is the result of the interaction of genetics and environment, which is triggered by uncontrolled cell proliferation caused by the malignant transformation of single cell gene mutation in normal tissues. Treating cancer requires killing or removing all tumor cells with tolerable side effects for the patient. With the development of surgery, radiotherapy and chemotherapy, targeted therapy and other technologies, the survival period of many tumor patients has been prolonged. Due to tumor metastasis and its heterogeneity, most patients develop drug resistance or relapse, and eventually die.
  • the memory capacity of the immune system can prevent tumor recurrence.
  • PD-1/PD-L1 antibody drugs are only effective in 20%-30% of patients. How to make more patients benefit from tumor immunotherapy is an urgent problem to be solved. This requires finding new immune checkpoint therapeutic targets for drug development.
  • the sialic acid-binding immunoglobulin-like lectin (Siglec) family is a class of classical immunoglobulin-like lectins, which can mediate cellular and cellular interactions by recognizing sialic acid-containing sugar chain structures. Interactions between cells or pathogens play an important regulatory role in innate and adaptive immunity. At present, 15 kinds of Siglec molecules of human origin and 9 kinds of murine origin have been found, and Siglec is specifically expressed on the surface of myeloid cells and immune cells.
  • Siglec family proteins are type I transmembrane proteins with immunoglobulin superfamily domains. Different family members have different numbers of "C2-set” immunoglobulin-like domains and "C2-set” domains.
  • the extracellular terminal immunoglobulin domain has a high similarity to the antibody variable region, called the "V-set" domain, and also has a transmembrane region and an intracellular segment.
  • Most Siglec intracellular segments contain immunoreceptor tyrosine-based inhibitory motifs (ITIMs), which play an immunosuppressive function.
  • Siglec-15 is a member of the Siglec family that is highly conserved in evolution. Its extracellular region has two immunoglobulin-like domains, the "C2-set” domain and the "V-set” domain, and the transmembrane region contains a
  • the 12kDa signal adaptor DNAX activating protein (DAP12) interacts with a key lysine residue (Lys274, human Siglec-15), and the interaction between Siglec-15 and DAP12 is through the ionic bond in the transmembrane region.
  • DAP12 has a very short extracellular domain ( ⁇ 20 amino acids), the transmembrane region contains an aspartate residue (Asp50, human DAP12), and the intracellular region has an ITAM (immunoreceptor tyrosine-based activating motif), which is ITAM recruits SYK to phosphorylate it for signaling.
  • ITAM immunofluoreceptor tyrosine-based activating motif
  • Hiruma et al. reported inhibition of the RAW264.7 mouse macrophage cell line (often used as an osteoclast precursor model), mouse bone marrow macrophages, and human osteoclast precursors by using a polyclonal antibody against Siglec-15 Differentiation into osteoclasts. Ishida-Kitagawa et al. demonstrated that the interaction of Siglec-15 with DAP12 and SYK signaling, as well as the interaction of Siglec-15 with sialylated ligands, are critical for osteoclast differentiation. These in vitro findings were quickly validated in transgenic mice. Hiruma et al.
  • Siglec-15 is expressed on tumor-associated macrophages and is induced by M-CSF, a cytokine that induces selective activation/polarization of macrophages.
  • M-CSF a cytokine that induces selective activation/polarization of macrophages.
  • Co-culture of sialyl-Tn+ tumor cell lines and M-CSF-induced human macrophages or Siglec-15+ myeloid cells increased myeloid TGF- ⁇ , a multifactorial protein that promotes epithelial-mesenchymal transition and metastasis of cancer cells. efficacious cytokines) production, which is dependent on DAP12 and SYK.
  • Siglec-15 is a new immunosuppressive checkpoint molecule in the tumor immune microenvironment and can be a potential tumor immunotherapy target.
  • Siglec-15 expressed on the surface of tumor cells or tumor-associated macrophages can interact with T cell surface receptors to inhibit the tumor-killing activity of T cells.
  • Siglec-15 can induce monocytes to differentiate into specific myeloid cells, which inhibit T cell function and promote tumor growth. Further in vitro experiments found that the tumor growth of Siglec-15 knockout mice was reduced, and after treatment with Siglec-15 monoclonal antibody, tumor growth in mice could be inhibited.
  • Siglec-15 is another molecule involved in immune escape in the tumor microenvironment and has potential as a therapeutic target.
  • the present invention provides an anti-Siglec-15 antibody and its application in the preparation of drugs.
  • Anti-Siglec-15 antibodies bind to Siglec-15 protein and exhibit many advantageous properties, including, for example, high affinity binding to Siglec-15 protein.
  • the antibodies of the present invention can reverse the Siglec-15-induced inhibition of PBMC proliferation and inhibit the Siglec-15 protein-mediated monocyte proliferation, thereby regulating immune responses.
  • the present invention also relates to methods of modulating immune responses using anti-Siglec-15 antibodies or antigen-binding fragments thereof.
  • the present invention also provides the application of the anti-Siglec-15 antibody or its antigen-binding fragment in the preparation of medicines for treating Siglec-15 related diseases or the preparation of medicines for treating tumors.
  • a first aspect of the invention provides isolated antibodies and antigen-binding fragments thereof that bind Siglec-15.
  • an anti-Siglec-15 antibody or antigen-binding fragment thereof of the invention comprises one or more CDR (complementarity determining region) sequences selected from the group consisting of SEQ ID NOs: 1, 2, 3, 4, 5 , 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 , 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 81.
  • one or more heavy chain CDR sequences selected from the group consisting of: SEQ ID NOs: 1, 2, 3, 4, 5, 11, 12, 13, 17, 18, 19, 20, 25, 26, 27, 28, 29, 35, 36, 37, and/or, one or more light chain CDR sequences selected from the group consisting of: SEQ ID NO: 6, 7, 8, 9, 10, 14, 15, 16, 21, 22, 23, 24, 30, 31, 32, 33, 34, 38, 39, 40, 81.
  • an anti-Siglec-15 antibody or antigen-binding fragment thereof of the invention comprises a heavy chain variable region comprising HCDR1, HCDR2 and HCDR3 sequences, and/or a light chain variable region comprising LCDR1, LCDR2 and LCDR3 sequence, where:
  • the heavy chain variable region HCDR1 sequence comprises an amino acid sequence selected from SEQ ID NOs: 1, 11, 17, 25, 35 and conservative modifications thereof;
  • the heavy chain variable region HCDR2 sequence comprises an amino acid sequence selected from SEQ ID NO: 1, 11, 17, 25, 35 and conservative modifications thereof; NO: 2, 3, 4, 12, 18, 19, 26, 27, 28, 36 and their conservatively modified amino acid sequences;
  • the heavy chain variable region HCDR3 sequence comprises a sequence selected from SEQ ID NO: 5, 13, 20 , 29, 37 and their conservatively modified amino acid sequences;
  • the light chain variable region LCDR1 sequence comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 6, 7, 14, 21, 30, 31, 38, 81 and conservative modifications thereof;
  • the light chain variable region LCDR2 The sequence comprises an amino acid sequence selected from SEQ ID NO: 8, 9, 15, 22, 23, 32, 33, 39 and conservative modifications thereof;
  • the light chain variable region LCDR3 sequence comprises an amino acid sequence selected from SEQ ID NO: 10, 16 , 24, 34, 40 and their conservatively modified amino acid sequences;
  • the present invention provides an isolated antibody or antigen-binding fragment thereof that binds Siglec-15, comprising a heavy chain variable region and/or a light chain variable region, wherein the heavy chain variable region comprises a variable region selected from the group consisting of Set of CDR sequences: SEQ ID NOs: 1, 2, 3, 4 and 5, the light chain variable region includes CDR sequences selected from the group of: SEQ ID NOs: 6, 7, 8, 9, 10 and 81.
  • the present invention provides an isolated antibody or antigen-binding fragment thereof that binds Siglec-15, comprising a heavy chain variable region and/or a light chain variable region, wherein the heavy chain variable region comprises a variable region selected from the group consisting of The CDR sequences of the following group: SEQ ID NOs: 11, 12 and 13, and the light chain variable region comprises CDR sequences selected from the following group: SEQ ID NOs: 14, 15 and 16.
  • the present invention provides an isolated antibody or antigen-binding fragment thereof that binds Siglec-15, comprising a heavy chain variable region and/or a light chain variable region, wherein the heavy chain variable region comprises a variable region selected from the group consisting of The CDR sequences of the following group: SEQ ID NOs: 17, 18, 19 and 20, and the light chain variable region comprises CDR sequences selected from the following group: SEQ ID NOs: 21, 22, 23 and 24.
  • the present invention provides an isolated antibody or antigen-binding fragment thereof that binds Siglec-15, comprising a heavy chain variable region and/or a light chain variable region, wherein the heavy chain variable region comprises a variable region selected from the group consisting of The CDR sequences of the following group: SEQ ID NOs: 25, 26, 27, 28 and 29, and the light chain variable region comprises CDR sequences selected from the following group: SEQ ID NOs: 30, 31, 32, 33 and 34.
  • the present invention provides an isolated antibody or antigen-binding fragment thereof that binds Siglec-15, comprising a heavy chain variable region and/or a light chain variable region, wherein the heavy chain variable region comprises a variable region selected from the group consisting of The CDR sequences of the following group: SEQ ID NOs: 35, 36 and 37, and the light chain variable region comprises CDR sequences selected from the following group: SEQ ID NOs: 38, 39 and 40.
  • the present invention provides an isolated antibody or antigen-binding fragment thereof that binds Siglec-15, comprising a heavy chain variable region and/or a light chain variable region, including HCDR1, HCDR2, and HCDR3 , the light chain variable region includes LCDR1, LCDR2 and LCDR3, wherein, the heavy chain variable region HCDR1 sequence is as shown in SEQ ID NO: 1, the HCDR2 sequence is selected from SEQ ID NO: 2, 3 and 4, and the HCDR3 sequence is as shown in SEQ ID NO: 1 As shown in NO: 5, the light chain variable region LCDR1 sequence is selected from SEQ ID NO: 6, 7 and 81, the LCDR2 sequence is selected from SEQ ID NO: 8 and 9, and the LCDR3 sequence is as shown in SEQ ID NO: 10.
  • the present invention provides an isolated antibody or antigen-binding fragment thereof that binds Siglec-15, comprising a heavy chain variable region and/or a light chain variable region including HCDR1, HCDR2 and HCDR3, the light chain variable region includes LCDR1, LCDR2 and LCDR3, wherein, the heavy chain variable region HCDR1 sequence is as shown in SEQ ID NO: 11, the HCDR2 sequence is as shown in SEQ ID NO: 12, and the HCDR3 sequence is as shown in SEQ ID NO: As shown in 13, the light chain variable region LCDR1 sequence is shown in SEQ ID NO: 14, the LCDR2 sequence is shown in SEQ ID NO: 15, and the LCDR3 sequence is shown in SEQ ID NO: 16.
  • the present invention provides an isolated antibody or antigen-binding fragment thereof that binds Siglec-15, comprising a heavy chain variable region and/or a light chain variable region including HCDR1, HCDR2 and HCDR3, the light chain variable region includes LCDR1, LCDR2 and LCDR3, wherein, the heavy chain variable region HCDR1 sequence is shown in SEQ ID NO: 17, the HCDR2 sequence is selected from SEQ ID NO: shown in SEQ ID NO: 18 and 19, and the HCDR3 sequence is shown in SEQ ID NO: 19 ID NO: 20, the light chain variable region LCDR1 sequence is shown in SEQ ID NO: 21, the LCDR2 sequence is selected from SEQ ID NO: 22 and 23, and the LCDR3 sequence is shown in SEQ ID NO: 24.
  • the heavy chain variable region HCDR1 sequence is shown in SEQ ID NO: 17
  • the HCDR2 sequence is selected from SEQ ID NO: shown in SEQ ID NO: 18 and 19
  • the HCDR3 sequence is shown in SEQ ID NO: 19 ID NO:
  • the present invention provides an isolated antibody or antigen-binding fragment thereof that binds Siglec-15, comprising a heavy chain variable region and/or a light chain variable region including HCDR1, HCDR2 and HCDR3, the light chain variable region includes LCDR1, LCDR2 and LCDR3, wherein, the heavy chain variable region HCDR1 sequence is as shown in SEQ ID NO: 25, the HCDR2 sequence is selected from SEQ ID NO: 26, 27 and 28, and the HCDR3 sequence is as shown in SEQ ID NO: 25 ID NO: 29, the light chain variable region LCDR1 sequence is selected from SEQ ID NO: 30 and 31, the LCDR2 sequence is selected from SEQ ID NO: 32 and 33, and the LCDR3 sequence is shown in SEQ ID NO: 34.
  • the present invention provides an isolated antibody or antigen-binding fragment thereof that binds Siglec-15, comprising a heavy chain variable region and/or a light chain variable region including HCDR1, HCDR2 and HCDR3, the light chain variable region includes LCDR1, LCDR2 and LCDR3, wherein, the heavy chain variable region HCDR1 sequence is as shown in SEQ ID NO:35, the HCDR2 sequence is as shown in SEQ ID NO:36, and the HCDR3 sequence is as shown in SEQ ID NO: As shown in 37, the light chain variable region LCDR1 sequence is shown in SEQ ID NO:38, the LCDR2 sequence is shown in SEQ ID NO:39, and the LCDR3 sequence is shown in SEQ ID NO:40.
  • the antibodies or antigen-binding fragments thereof of the present invention can be murine antibodies, chimeric antibodies, humanized antibodies, fully human antibodies or fragments thereof, preferably fully human antibodies, humanized antibodies or fragments thereof.
  • the present invention provides an isolated antibody or antigen-binding fragment thereof that binds Siglec-15, comprising: a heavy chain variable region of SEQ ID NO:41 or a variant thereof; and/or comprising SEQ ID NO:42 or the light chain variable region of a variant thereof.
  • the present invention provides an isolated antibody or antigen-binding fragment thereof that binds Siglec-15, comprising: a heavy chain variable region of SEQ ID NO:43 or a variant thereof; and/or comprising SEQ ID NO:44 or the light chain variable region of a variant thereof.
  • the present invention provides an isolated antibody or antigen-binding fragment thereof that binds Siglec-15, comprising: a heavy chain variable region of SEQ ID NO:45 or a variant thereof; and/or comprising SEQ ID NO:46 or the light chain variable region of a variant thereof.
  • the present invention provides an isolated antibody or antigen-binding fragment thereof that binds Siglec-15, comprising: a heavy chain variable region of SEQ ID NO:47 or a variant thereof; and/or comprising SEQ ID NO:48 or the light chain variable region of a variant thereof.
  • the present invention provides an isolated antibody or antigen-binding fragment thereof that binds Siglec-15, comprising: a heavy chain variable region of SEQ ID NO:49 or a variant thereof; and/or comprising SEQ ID NO:50 or the light chain variable region of a variant thereof.
  • the present invention provides an isolated antibody or antigen-binding fragment thereof that binds Siglec-15, comprising: A heavy chain variable region of an amino acid sequence of 99% homology; and/or an amino acid sequence comprising at least 90%, 95%, 96%, 97%, 98% or 99% homology to SEQ ID NO:42 light chain variable region.
  • the present invention provides an isolated antibody or antigen-binding fragment thereof that binds Siglec-15, comprising: comprising at least 90%, 95%, 96%, 97%, 98% or A heavy chain variable region of an amino acid sequence of 99% homology; and/or an amino acid sequence comprising at least 90%, 95%, 96%, 97%, 98% or 99% homology to SEQ ID NO:44 light chain variable region.
  • the present invention provides an isolated antibody or antigen-binding fragment thereof that binds Siglec-15, comprising: A heavy chain variable region of an amino acid sequence of 99% homology; and/or an amino acid sequence comprising at least 90%, 95%, 96%, 97%, 98% or 99% homology to SEQ ID NO:46 light chain variable region.
  • the invention provides an isolated antibody or antigen-binding fragment thereof that binds Siglec-15, comprising: A heavy chain variable region of an amino acid sequence of 99% homology; and/or an amino acid sequence comprising at least 90%, 95%, 96%, 97%, 98% or 99% homology to SEQ ID NO:48 light chain variable region.
  • the invention provides an isolated antibody or antigen-binding fragment thereof that binds Siglec-15, comprising: A heavy chain variable region of an amino acid sequence of 99% homology; and/or an amino acid sequence comprising at least 90%, 95%, 96%, 97%, 98% or 99% homology to SEQ ID NO:50 light chain variable region.
  • a second aspect of the present invention provides an isolated humanized antibody or antigen-binding fragment thereof that binds Siglec-15, the humanized antibody comprising one or more sites selected from the group consisting of the sequence shown in SEQ ID NO:41 Introduced mutated heavy chain variable regions at: M3, K19, S40, E42, R44, P61, T65, S77, T78, S84, S88, M93, V97, P117 and/or S120 sites, and/or at SEQ ID
  • the light chain variable region of the sequence shown in NO: 42 is mutated at one or more sites selected from the group consisting of: V3, L4, A9, A12, V13, L15, Q17, A19, S22, K24, D32, Q46 , P47, E59, I62, A64, N78, H80, P81, V82, E83, E84, A87, A104 and/or L110.
  • the present invention provides an isolated humanized antibody or antigen-binding fragment thereof that binds Siglec-15, comprising introduction at one or more sites selected from the group consisting of the sequence set forth in SEQ ID NO:41 Mutated heavy chain variable regions: M3Q, K19R, S40A, E42G, R44G, P61A, T65K, S77N, T78S, S84N, S88A, M93V, V97A, P117Q and/or S120T, and/or, in SEQ ID NO:42
  • the light chain variable region of the indicated sequence is mutated at one or more sites selected from the group consisting of: V3Q, L4M, A9S, A12S, V13A, L15V, Q17D, A19V, S22T, K24R, D32E, Q46K, P47A, E59Q, I62V, A64S, N78T, H80S, P81S, V82L, E83Q, E84P, A87F, A
  • the present invention provides an isolated humanized antibody or antigen-binding fragment thereof that binds Siglec-15, comprising a heavy chain variable region and/or a light chain variable region, wherein the heavy chain variable region sequence is selected from the group consisting of SEQ ID NOs: 51, 53, 55 and 57, and the light chain variable region is selected from the group consisting of SEQ ID NOs: 52, 54, 56, 58 and 82.
  • the present invention provides an isolated humanized antibody or antigen-binding fragment thereof that binds Siglec-15, the humanized antibody comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region
  • the region sequence includes the sequence shown in SEQ ID NO: 51 or a variant thereof
  • the light chain variable region sequence includes the sequence shown in SEQ ID NO: 52 or a variant thereof.
  • the present invention provides an isolated humanized antibody or antigen-binding fragment thereof that binds Siglec-15, comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region sequence comprises SEQ The sequence shown in ID NO: 53 or a variant thereof, the light chain variable region sequence includes the sequence shown in SEQ ID NO: 54 or a variant thereof.
  • the present invention provides an isolated humanized antibody or antigen-binding fragment thereof that binds Siglec-15, comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region sequence comprises SEQ The sequence shown in ID NO: 55 or a variant thereof, the light chain variable region sequence includes the sequence shown in SEQ ID NO: 56 or a variant thereof.
  • the present invention provides an isolated humanized antibody or antigen-binding fragment thereof that binds Siglec-15, comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region sequence comprises SEQ The sequence shown in ID NO: 57 or a variant thereof, the light chain variable region sequence includes the sequence shown in SEQ ID NO: 58 or a variant thereof.
  • the present invention provides an isolated humanized antibody or antigen-binding fragment thereof that binds Siglec-15, comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region sequence comprises SEQ The sequence shown in ID NO: 53 or a variant thereof, the light chain variable region sequence includes the sequence shown in SEQ ID NO: 56 or a variant thereof.
  • the present invention provides an isolated humanized antibody or antigen-binding fragment thereof that binds Siglec-15, comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region sequence comprises SEQ The sequence shown in ID NO: 53 or a variant thereof, the light chain variable region sequence includes the sequence shown in SEQ ID NO: 58 or a variant thereof.
  • the present invention provides an isolated humanized antibody or antigen-binding fragment thereof that binds Siglec-15, comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region sequence comprises SEQ The sequence shown in ID NO: 53 or a variant thereof, the light chain variable region sequence includes the sequence shown in SEQ ID NO: 82 or a variant thereof.
  • a third aspect of the present invention provides an isolated humanized antibody or antigen-binding fragment thereof that binds Siglec-15, comprising a mutation introduced at one or more sites selected from the group consisting of the sequence shown in SEQ ID NO: 45 Heavy chain variable region: E1, Q5, L11, V12, R13, L20, T23, K38, R40, T41, E42, A61, P62, K67, A68, A72, S76, N77, L81, H82, T85, T87, The V97 and/or S113 sites, and/or, the mutated light chain variable region is introduced at one or more sites of the sequence shown in SEQ ID NO: 46 selected from the group consisting of: S8, F12, A18, Y36, L41, P43, K45, V47, T58, D74, G78, N81, I82, P84 and/or V89 sites.
  • the present invention provides an isolated humanized antibody or antigen-binding fragment thereof that binds Siglec-15, comprising introduction at one or more sites selected from the group consisting of the sequence set forth in SEQ ID NO:45 Mutated heavy chain variable regions: E1Q, Q5V, L11V, V12K, R13K, L20V, T23K, K38R, R40A, T41P, E42G, A61S, P62Q, K67R, A68V, A72R, S76T or S76A, N77S, L81M, H82E, T85S, T87R, V97A and/or S113T sites, and/or a light chain variable region with mutations introduced at one or more sites selected from the group consisting of S8P, F12A, A18V in the sequence shown in SEQ ID NO: 46 , Y36H, L41E, P43G, K45R, V47L, T58K, D74E, G78T, N81S, I82L
  • the present invention provides an isolated humanized antibody or antigen-binding fragment thereof that binds Siglec-15, comprising a heavy chain variable region and/or a light chain variable region, wherein the heavy chain variable region sequence is selected from the group consisting of SEQ ID NOs: 59, 61, 63 and 65, and the light chain variable region is selected from the group consisting of SEQ ID NOs: 60, 62, 64 and 66.
  • the present invention provides an isolated humanized antibody or antigen-binding fragment thereof that binds Siglec-15, comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region sequence comprises SEQ The sequence shown in ID NO: 59 or a variant thereof, the light chain variable region sequence includes the sequence shown in SEQ ID NO: 60 or a variant thereof.
  • the present invention provides an isolated humanized antibody or antigen-binding fragment thereof that binds Siglec-15, comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region sequence comprises SEQ The sequence shown in ID NO: 61 or a variant thereof, the light chain variable region sequence includes the sequence shown in SEQ ID NO: 62 or a variant thereof.
  • the present invention provides an isolated humanized antibody or antigen-binding fragment thereof that binds Siglec-15, comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region sequence comprises SEQ The sequence shown in ID NO: 63 or a variant thereof, the light chain variable region sequence includes the sequence shown in SEQ ID NO: 64 or a variant thereof.
  • a fourth aspect of the present invention provides an isolated humanized antibody or antigen-binding fragment thereof that binds Siglec-15, which comprises a mutation introduced at one or more sites selected from the group consisting of the sequence shown in SEQ ID NO: 47 Heavy chain variable regions: E1, Q5, P9, V10, L11, V12, M20, E23, K38, S40, K43, S44, N61, K67, A68, L70, V72, S76, N84, T87, S91 and/or S119 site, and/or the light chain variable region of the sequence set forth in SEQ ID NO: 48 at one or more sites selected from the group consisting of: V3, L4, A9, A12, V13, L15, Q17 , A19, S22, R43, R46, P47, E59, I62, A64, R72, D80, P81, V82, E83, A84, D85, V87, A104 and/or L110 sites.
  • the invention provides an isolated humanized antibody or antigen-binding fragment thereof that binds Siglec-15, comprising introduction at one or more sites selected from the group consisting of the sequence set forth in SEQ ID NO:47 Mutated heavy chain variable regions: E1Q, Q5V, P9A, V10E, L11V, V12K, M20V, E23K, K38R, S40A, K43Q, S44G, N61A, K67R, A68V, L70M, V72R, S76T, N84S, T87R, S91T and /or S119T site, and/or a light chain variable region with mutations introduced at one or more sites in the sequence shown in SEQ ID NO: 48 selected from the group consisting of: V3Q, L4M, A9S, A12S, V13A, L15V , Q17D, A19V, S22T, R43K, R46K, P47A, E59Q, I62V, A64S, R72G
  • the present invention provides an isolated humanized antibody or antigen-binding fragment thereof that binds Siglec-15, comprising a heavy chain variable region and/or a light chain variable region, wherein the heavy chain variable region sequence is selected from the group consisting of SEQ ID NOs: 67, 69, 71 and 73, and the light chain variable region is selected from the group consisting of SEQ ID NOs: 68, 70, 72 and 74.
  • the present invention provides an isolated humanized antibody or antigen-binding fragment thereof that binds Siglec-15, comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region sequence comprises SEQ The sequence shown in ID NO: 67 or a variant thereof, the light chain variable region sequence includes the sequence shown in SEQ ID NO: 68 or a variant thereof.
  • the present invention provides an isolated humanized antibody or antigen-binding fragment thereof that binds Siglec-15, comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region sequence comprises SEQ The sequence shown in ID NO: 69 or a variant thereof, the light chain variable region sequence includes the sequence shown in SEQ ID NO: 70 or a variant thereof.
  • the present invention provides an isolated humanized antibody or antigen-binding fragment thereof that binds Siglec-15, comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region sequence comprises SEQ The sequence shown in ID NO: 71 or a variant thereof, the light chain variable region sequence includes the sequence shown in SEQ ID NO: 72 or a variant thereof.
  • variants of the antibodies or antigen-binding fragments thereof of the invention may comprise one, two or three conservatively modified amino acid substitutions.
  • capital English letters + numbers represent the amino acid residues at the numerical position
  • “capital English letters 1 + numbers + capital English letters 2” means that the amino acid residues at the numerical positions are composed of a certain An amino acid is replaced with another amino acid residue
  • "E1” means that the amino acid residue at position 1 of amino acid number 1 is glutamic acid
  • "E1Q” means that glutamic acid at position 1 of amino acid number is replaced with glutamine
  • Q5" represents that the amino acid residue at the 5th position of the amino acid number is glutamine
  • “Q5V” represents that the glutamine of the amino acid number 5 position is replaced by valine
  • the antibody or antigen-binding fragment thereof of the invention may comprise: a human heavy chain constant region or a variant thereof, wherein the variant comprises up to 20 conservatively modified amino acid substitutions; and/or a human light chain constant region region or a variant thereof, wherein the variant comprises up to 20 conservatively modified amino acid substitutions.
  • the variant may comprise up to 10 conservatively modified amino acid substitutions.
  • the variant may comprise up to 5 conservatively modified amino acid substitutions.
  • the variant may comprise up to 3 conservatively modified amino acid substitutions.
  • the human heavy chain constant region or variant thereof may be an IgGl, IgG2, IgG3, IgG4, IgA, IgE, IgM or IgD constant region or variant thereof, preferably an IgGl or IgG4 constant region or variant thereof .
  • the numbering system of amino acid residues in the antibody or antigen-binding fragment thereof of the present invention is the numbering system of the EU index of Kabat.
  • the antibodies of the invention, or antigen-binding fragments thereof can bind Siglec-15 with a KD of 930 pM or less.
  • the antibody or antigen-binding fragment thereof can bind Siglec-15 with a KD of 614 pM or less.
  • the antibody or antigen-binding fragment thereof can bind Siglec-15 with a KD of 325 pM or less.
  • the antibody or antigen-binding fragment thereof can bind Siglec-15 with a KD of 202 pM or less.
  • the antibody or antigen-binding fragment thereof can bind Siglec-15 with a KD of 109 pM or less.
  • the antibody or antigen-binding fragment thereof can bind Siglec-15 with a KD of 85.6 pM or less. In another embodiment, the antibody or antigen-binding fragment thereof can bind Siglec-15 with a KD of 80.6 pM or less. In another embodiment, the antibody or antigen-binding fragment thereof can bind Siglec-15 with a KD of 72.4 pM or less. In another embodiment, the antibody or antigen-binding fragment thereof can bind Siglec-15 with a KD of 68.3 pM or less.
  • the KD value can be measured by any valid method.
  • dissociation constants are measured using bioluminescence interferometry (eg, the ForteBio Octet method described in Example 2).
  • dissociation constants can be measured using surface plasmon resonance techniques (eg, Biacore) or Kinexa.
  • antibody antigen-binding fragments of the present invention include, but are not limited to, antibody fragments that are Fab, Fab', F(ab')2, Fv, or scFv, sdFv (disulfide-linked Fv).
  • Fab fragment a monovalent fragment composed of VL, VH, CL and CH1 domains
  • F(ab')2 fragment a bivalent fragment comprising two Fab fragments connected by a disulfide bridge in the hinge region
  • Fd fragment composed of VH and CH1 domains
  • Fv fragment composed of VL and VH domains of the antibody one-arm
  • scFv fragment a monovalent molecule formed by pairing of VL and VH regions.
  • the anti-Siglec-15 antibodies or antigen-binding fragments thereof of the invention can bind to human Siglec-15. In other embodiments, the anti-Siglec-15 antibodies or antigen-binding fragments thereof of the invention can bind to monkey Siglec-15. In other embodiments, the anti-Siglec-15 antibodies or antigen-binding fragments thereof of the invention can bind to murine Siglec-15.
  • the anti-Siglec-15 antibodies or antigen-binding fragments thereof of the invention bind to the same or different epitope as Siglec-15.
  • the antibody fragments of the invention are bispecific antibodies.
  • a fifth aspect of the invention also includes bispecific antibodies comprising any of the Siglec-15 binding antibodies or antigen-binding fragments thereof described above.
  • the sixth aspect of the present invention also includes nucleic acid sequences encoding the anti-Siglec-15 antibodies of the present invention and antigen-binding fragments thereof.
  • the seventh aspect of the present invention also includes an expression vector comprising a nucleic acid sequence encoding an antibody or antigen-binding fragment thereof of the present invention.
  • the eighth aspect of the present invention also includes a host cell comprising the expression vector of the seventh aspect.
  • the ninth aspect of the present invention also includes a method for preparing an antibody of the present invention or an antigen-binding fragment thereof, the method comprising: (a) culturing in a medium under conditions in which the nucleic acid sequence is expressed or a host cell of nucleic acid of an antigen-binding fragment thereof, thereby producing a polypeptide comprising light and heavy chain variable regions; and (b) recovering the polypeptide from the host cell or culture medium.
  • the tenth aspect of the invention also includes a composition comprising an antibody or antigen-binding fragment thereof of the invention in combination with a pharmaceutically acceptable carrier or diluent.
  • the eleventh aspect of the invention also includes an immunoconjugate comprising an anti-Siglec-15 antibody or antigen-binding fragment thereof of the invention linked to a therapeutic agent (eg, bacterial toxin or radiotoxin).
  • a therapeutic agent eg, bacterial toxin or radiotoxin.
  • cytotoxic agents include: taxol, cytochalasin B, mitomycin, etoposide, and vincristine or other antimetabolites , alkylating agents, antibiotics and antimitotics.
  • the twelfth aspect of the present invention further includes the anti-Siglec-15 antibody or its antigen-binding fragment according to the first aspect of the present invention, the composition according to the tenth aspect, the immunoconjugate according to the eleventh aspect, and the fifth aspect. The application of the bispecific antibody in the preparation of a medicine for treating Siglec-15 related diseases.
  • the anti-Siglec-15 antibody or its antigen-binding fragment according to the first aspect of the present invention the composition according to the tenth aspect, the immunoconjugate according to the eleventh aspect, and the bispecific antibody according to the fifth aspect of the present invention
  • Siglec-15 related diseases for the treatment of Siglec-15 related diseases.
  • a method for treating Siglec-15 related diseases comprising administering the anti-Siglec-15 antibody or its antigen-binding fragment according to the first aspect of the present invention, the composition according to the tenth aspect, to a subject in need thereof, The immunoconjugate of the eleventh aspect or the bispecific antibody of the fifth aspect.
  • the Siglec-15-related diseases described in the present invention include, but are not limited to, cancer or bone disease-related diseases.
  • the cancer or bone disease related disease can be Siglec-15 positive cancer and bone disease;
  • the cancer includes, but is not limited to, leukemia, melanoma, head and neck cancer, glioblastoma cells, breast cancer, ovarian cancer, gastric cancer, urothelial cancer, gastroesophageal cancer, esophageal cancer, endometrial cancer, colon cancer, Liver cancer, lung cancer or bladder cancer; wherein the leukemia includes Acute lymphocytic leukemia (ALL), Acute myelogenous leukemia (AML), Chronic lymphocytic leukemia (CLL), Chronic myelogenous leukemia (CML);
  • ALL Acute lymphocytic leukemia
  • AML Acute myelogenous leukemia
  • CLL Chronic lymphocytic leukemia
  • CML Chronic myelogenous leukemia
  • the bone diseases include, but are not limited to, osteoporosis, bone loss, osteoarthritis, osteomalacia, and the like.
  • the present invention also includes the use of the anti-Siglec-15 antibody or the antigen-binding fragment thereof of the present invention in the preparation of a drug for reversing the Siglec-15-hFc-mediated inhibition of PBMC proliferation.
  • the present invention also includes the use of the anti-Siglec-15 antibody or the antigen-binding fragment thereof of the present invention in the preparation of a medicament for inhibiting Siglec-15 protein-mediated monocyte proliferation.
  • the present invention also includes the use of the anti-Siglec-15 antibody or antigen-binding fragment thereof of the present invention in the preparation of a medicament for inhibiting the survival of monocytes mediated by Siglec-15 protein.
  • the present invention also includes the use of the anti-Siglec-15 antibody or antigen-binding fragment thereof of the present invention in the preparation of a medicament for regulating immune response.
  • the thirteenth aspect of the present invention further includes the anti-Siglec-15 antibody or its antigen-binding fragment according to the first aspect of the present invention, the composition according to the tenth aspect, the immunoconjugate according to the eleventh aspect, and the fifth aspect.
  • the anti-Siglec-15 antibody or its antigen-binding fragment according to the first aspect of the present invention the composition according to the tenth aspect, the immunoconjugate according to the eleventh aspect, and the bispecific antibody according to the fifth aspect of the present invention For inhibiting tumor cell growth.
  • a method for inhibiting tumor cell growth comprising administering the anti-Siglec-15 antibody or its antigen-binding fragment according to the first aspect of the present invention, the composition of the tenth aspect, the tenth aspect to a subject in need
  • the immunoconjugate of one aspect or the bispecific antibody of the fifth aspect comprising administering the anti-Siglec-15 antibody or its antigen-binding fragment according to the first aspect of the present invention, the composition of the tenth aspect, the tenth aspect to a subject in need.
  • an anti-Siglec-15 antibody or antigen-binding fragment thereof can be combined with a second therapeutic agent or therapeutic modality.
  • treatment with an anti-Siglec-15 antibody or antigen-binding fragment thereof may be combined with chemotherapy.
  • treatment with an anti-Siglec-15 antibody or antigen-binding fragment thereof may be combined with radiotherapy.
  • an anti-Siglec-15 antibody or antigen-binding fragment thereof can be combined with another therapeutic antibody for the treatment of cancer.
  • the present invention obtains a novel antibody or antigen-binding fragment with high affinity to Siglec-15, its preparation method, a composition containing the same, an immunoconjugate or a bispecific antibody, and the present invention obtains an anti-Siglec-15 antibody or its Antigen-binding fragments have methods of modulating immune responses and have therapeutic effects on tumors.
  • Figure 1 shows the binding curve and EC50 value of anti-Siglec-15 chimeric antibody to 293T-hu-S15.
  • Figure 2A shows the reversal curve and EC50 value of chimeric antibody 21F6C6 on the inhibition of Siglec-15 protein-induced PBMC proliferation.
  • Figure 2B shows the reverse curve and EC50 value of chimeric antibody 75E1F2 on the inhibition of Siglec-15 protein-induced PBMC proliferation.
  • Figure 2C is a graph showing the reversal and EC50 values of chimeric antibody 174C11C9 on the inhibition of Siglec-15 protein-induced PBMC proliferation.
  • Figure 2D shows the reversal curve and EC50 value of chimeric antibody 124B11F6 on the inhibition of Siglec-15 protein-induced PBMC proliferation.
  • Figure 2E shows the reversal curve and EC50 value of the inhibition of Siglec-15 protein-induced PBMC proliferation by chimeric antibody 255C12B10.
  • Figure 3 shows that anti-Siglec-15 chimeric antibody inhibits Siglec-15 protein-mediated monocyte proliferation.
  • Figure 4A is a diagram of the humanization design of the heavy chain variable region of the 21F6C6 chimeric antibody.
  • Figure 4B is a diagram of the humanization design of the light chain variable region of the 21F6C6 chimeric antibody.
  • Figure 4C is a diagram of the humanization design of the heavy chain variable region of the 124B11F6 chimeric antibody.
  • Figure 4D is a diagram of the humanization design of the light chain variable region of the 124B11F6 chimeric antibody.
  • Figure 4E is a diagram of the humanization design of the heavy chain variable region of the 174C11C9 chimeric antibody.
  • Figure 4F is a diagram of the humanization design of the light chain variable region of the 174C11C9 chimeric antibody.
  • Figure 5A is a graph showing the percent reversal of Siglec-15 protein-mediated inhibition of PBMC proliferation by humanized antibodies 21F6C6-hH1L1, 21F6C6-hH2L2 and EC50 values.
  • Figure 5B is a graph showing the percentage of humanized antibodies 21F6C6-hH2L3, 21F6C6-hH3L3 reversed Siglec-15 protein-mediated inhibition of PBMC proliferation and EC50 values.
  • Figure 5C is a graph showing the percentage of humanized antibodies 21F6C6-hH2L4, 21F6C6-hH4L4 reversed Siglec-15 protein-mediated inhibition of PBMC proliferation and EC50 values.
  • Figure 5D is a graph showing the percent reversal of Siglec-15 protein-mediated inhibition of PBMC proliferation by humanized antibodies 124B11F6-hH1L1, 124B11F6-hH2L2, 124B11F6-hH3L3 and EC50 values.
  • Figure 5E is a graph showing the percentage of humanized antibodies 174C11C9-hH1L1, 174C11C9-hH2L2, 174C11C9-hH3L3 reversed Siglec-15 protein-mediated inhibition of PBMC proliferation and EC50 values.
  • Figure 6 is a graph showing that anti-Siglec-15 humanized antibody inhibits Siglec-15 protein-mediated monocyte proliferation.
  • Figure 7 is the growth curve of the tumor volume of the mice in the control group and the treatment group in the MC38-hSiglec15 tumor model.
  • FIG. 8 is the change curve of the body weight of the control group and the treatment group with the treatment time in the MC38-hSiglec15 tumor model.
  • the gene sequences encoding the antigens and detection proteins of the present invention are obtained, and the antibody heavy chain Fc fragment (such as Human IgG1) or His tag was recombined, expressed and purified by HEK293 or Expi293 cells to obtain the antigen and detection protein of the present invention.
  • the antibody heavy chain Fc fragment such as Human IgG1 or His tag was recombined, expressed and purified by HEK293 or Expi293 cells to obtain the antigen and detection protein of the present invention.
  • the protein manufacturer is Beijing Baipsis Biotechnology Co., Ltd., and the product number is SG5-H5253 (Fc tag) and SG5-H52H3 (His tag), wherein the human Siglec-15 extracellular region sequence is as shown in SEQ ID NO: 75, wherein 1-19 amino acid residues are signal peptide sequences, and 40-158 amino acid residues are "V" -set” domain, amino acid residues 168-251 are "C2-set” domain; the sequence of recombinant protein (hS15-hFc for short) obtained by linking the full-length extracellular region of human Siglec-15 and human IgG1 Fc fragment is shown in SEQ ID NO:76, wherein, amino acid residues 1-244 are the full-length extracellular region sequence of Siglec-15, and amino acid residues 253-483 are human IgG1 Fc sequence; Siglec-15 first domain (Domain 1, comprising " The sequence of the recombinant protein (hS15-D1-hFc for
  • the amino acid residue is the first domain of Siglec-15 (among which the 25-143 amino acid residues are the Siglec-15 "V-set” domain sequence), the 153-159 amino acid residues are the linker (Linker) sequence, 160
  • the amino acid residue at position 390 is the sequence of human IgG1 Fc; the protein sequence obtained by linking the full-length extracellular region of human Siglec-15 with the His-tag sequence is shown in SEQ ID NO: 78, wherein the amino acid residues at positions 1-244 are the full-length human Siglec-15 protein sequence. Long extracellular region sequence, amino acid residues 253-262 are His tag sequences.
  • the mouse and cynomolgus monkey Siglec-15 proteins for detection were commercial products and were purchased from Beijing Baipsis Biotechnology Co., Ltd., the product numbers were SG5-M52H7 and SG5-C52H6, respectively.
  • the protein sequence obtained by linking the full-length extracellular region of cynomolgus monkey Siglec-15 with the His tag sequence is shown in SEQ ID NO: 79, wherein amino acid residues 1-244 are the full-length extracellular region sequence of monkey Siglec-15, 253
  • the -262 amino acid residue is the His-tag sequence.
  • the protein sequence obtained by connecting the full-length extracellular region of mouse Siglec-15 and the His tag sequence is shown in SEQ ID NO: 80, wherein amino acid residues 1-239 are the full-length extracellular region sequence of mouse Siglec-15, 248- The 257th amino acid residue is the His-tag sequence.
  • mice Fifteen mice (5 C57bl/6, 5 balb/c, 5 SJL) were immunized with adjuvanted emulsified hS15-hFc and 2 weeks later with hS15-hFc or hS15-D1-hFc.
  • Antiserum titers were assessed by taking sera for ELISA experiments. Mice with higher serum titers were selected for splenocyte fusion. 3 days after the last booster immunization, spleen cells were taken for fusion, and a total of 5 rounds of fusion were performed by electrofusion, and 50 96-well plates were plated with hybridoma cells obtained after each fusion. The hybridoma supernatant was subjected to a binding activity assay to screen out positive clones and further subcloned. Positive clones were screened for sequencing by combining activity experiments and in vitro immune cell function experiments.
  • RESULTS Five positive hybridoma clones were screened by combining activity test and in vitro immune cell function test, which were 21F6C6, 75E1F2, 124B11F6, 174C11C9 and 255C12B10. The heavy chain variable region and light chain variable region of the five hybridoma clones were The sequences are shown below.
  • underlined sequences are HCDR1, HCDR2 and HCDR3, respectively, and the amino acid sequences are shown in SEQ ID NOs: 1, 2 and 5, respectively.
  • SEQ ID NO: 3 and 4 are obtained by 1 or 2 amino acid substitutions on SEQ ID NO: 2.
  • underlined sequences are respectively LCDR1, LCDR2 and LCDR3, and the amino acid sequences are respectively shown in SEQ ID NOs: 6, 8 and 10.
  • SEQ ID NO: 7 and 9 are obtained by performing 1 amino acid substitution on SEQ ID NO: 6 and 8, respectively.
  • underlined sequences are HCDR1, HCDR2 and HCDR3, respectively, and the amino acid sequences are shown in SEQ ID NOs: 11, 12 and 13, respectively.
  • the underlined sequences are respectively LCDR1, LCDR2 and LCDR3, and the amino acid sequences are shown in SEQ ID NOs: 14, 15 and 16, respectively.
  • underlined sequences are HCDR1, HCDR2 and HCDR3, respectively, and the amino acid sequences are shown in SEQ ID NOs: 17, 18 and 20, respectively.
  • SEQ ID NO: 19 was obtained by 2 amino acid substitutions on SEQ ID NO: 18.
  • underlined sequences are respectively LCDR1, LCDR2 and LCDR3, and the amino acid sequences are respectively shown in SEQ ID NOs: 21, 22 and 24.
  • SEQ ID NO: 23 is obtained by 1 amino acid substitution on SEQ ID NO: 22.
  • underlined sequences are respectively LCDR1, LCDR2 and LCDR3, and the amino acid sequences are respectively shown in SEQ ID NOs: 30, 32 and 34.
  • SEQ ID NOs: 31 and 33 are obtained by performing 1 amino acid substitution on SEQ ID NOs: 30 and 32, respectively.
  • underlined sequences are HCDR1, HCDR2 and HCDR3, respectively, and the amino acid sequences are shown in SEQ ID NOs: 35, 36 and 37, respectively.
  • the underlined sequences are respectively LCDR1, LCDR2 and LCDR3, and the amino acid sequences are shown in SEQ ID NOs: 38, 39 and 40, respectively.
  • the underlined sequences are CDR1, CDR2 and CDR3 of the heavy chain variable region or the light chain variable region, respectively, and the sequences separated by the three CDR sequences are the heavy chain variable region or the light chain variable region.
  • variable regions of antibodies obtained by hybridoma screening and the constant regions of human IgG1 were synthesized into chimeric antibodies, named 21F6C6, 75E1F2, 124B11F6, 174C11C9 and 255C12B10 chimeric antibodies, respectively.
  • the Siglec-15 protein from different species was used for binding activity experiments with chimeric antibodies.
  • the Siglec-15 protein from human/mouse/cynomolgus monkey species was obtained from Beijing Biopsis Biotechnology Co., Ltd.
  • the antigen was coated with 0.5 ⁇ g/ml, and the antibody was diluted from 1 ⁇ g/ml and incubated with the antigen.
  • the secondary antibody was Anti-Human IgG antibody labeled with horseradish peroxidase, and the OD 450 value was read after adding the substrate.
  • the five anti-Siglec-15 chimeric antibodies all had binding activity to human Siglec-15 and cynomolgus monkey Siglec-15, and the chimeric antibodies derived from 124B11F6, 174C11C9 and 255C12B10 hybridomas had binding activity to murine Siglec-15.
  • Table 2 shows the EC50 values of anti-Siglec-15 chimeric antibodies binding to Siglec-15 antigens of different species.
  • Table 2 EC 50 values of anti-Siglec-15 chimeric antibodies binding to Siglec-15 antigens of different species
  • the HEK293T cell line overexpressing human Siglec-15 was purchased from Kangyuan Bochuang (HEK293T-hu-S15 cell line, Cat. No. KC-1314), and the purified anti-Siglec-15 chimeric antibody was diluted with HEK293T-hu-S15 at 100nM gradient. The cell lines were incubated at 4°C for 30 minutes, and anti-human IgG (Fc specific)-FITC (Cat. No.: F9512) secondary antibody was added to the samples for 30 minutes and then analyzed by flow cytometry.
  • Kangyuan Bochuang HEK293T-hu-S15 cell line, Cat. No. KC-1314
  • the purified anti-Siglec-15 chimeric antibody was diluted with HEK293T-hu-S15 at 100nM gradient.
  • the cell lines were incubated at 4°C for 30 minutes, and anti-human IgG (Fc specific)-FITC (Cat. No.
  • Biacore8K was used for affinity analysis.
  • Anti-human Fc antibody immobilized on a CM5 chip was used to capture the test antibody.
  • the test antibody stock solution was diluted to 5 ⁇ g/mL and injected into the experimental channel at a flow rate of 10 ⁇ L/min for about 500RU.
  • the analyte is Human Siglec-15, His Tag (Cat.No.SG5-H52H3), the diluted human Siglec-15 protein is injected into the experimental channel and the reference channel at a flow rate of 30 ⁇ L/min in turn, and the binding time is 150s , the dissociation time is 700s.
  • KD values for each antibody were calculated using Biacore 8K analysis software.
  • Table 3 shows the results of affinity analysis between the anti-Siglec-15 chimeric antibody and Siglec-15 protein.
  • Table 4 shows the competition parameters of anti-Siglec-15 chimeric antibodies, 60%-100% means no competition at all, indicating that the antigenic epitopes are inconsistent or partially identical; 20%-60% means partial competition, indicating that the antigenic epitopes are partially identical ; ⁇ 20% indicates complete competition, indicating that the antigenic epitopes are identical.
  • Anti-Siglec-15 chimeric antibody can reverse Siglec-15 protein-mediated inhibition of PBMC proliferation
  • PBMC peripheral blood mononuclear cells
  • serially diluted anti-Siglec-15 chimeric antibody and hS15-hFc protein 0.5 ⁇ g/ml
  • Soluble OKT3 0.5ng/ml, eBioscience
  • celltiterglo Promega
  • Example 8 Anti-Siglec-15 chimeric antibody can inhibit Siglec-15 protein-mediated monocyte survival
  • the cryopreserved CD14+ monocytes isolated from human PBMC were recovered, incubated with different concentrations of anti-Siglec-15 chimeric antibody and hS15-hFc protein at 37°C for 30 minutes, and then 1 ⁇ 10 5 CD14+ monocytes were added. After 6 days of culture, XTT (Roche, Cat. No. 11465015001) was added to the plates, and after 2 hours of culture, cell viability was measured by reading OD450-OD690.
  • hS15-hFc protein shown in Figure 3 could induce the survival and proliferation of CD14+ monocytes, and the anti-Siglec-15 chimeric antibody could gradiently inhibit the Siglec-15 protein-mediated monocyte proliferation.
  • the chimeric antibodies 21F6C6, 124B11F6 and 174C11C9 were humanized and designed to provide four heavy chains and four light chains, respectively, as shown in Table 5 below.
  • 21F6C6, 124B11F6 and 174C11C9 humanized sequences were expressed (Table 6).
  • the LCDR1 of 21F6C6-hH2L4 was point mutated to obtain a humanized antibody 21F6C6-hH2L4V, the post-translational modification site of isomerization was removed, and the light chain variable region sequence was SEQ ID NO: 82 (21F6C6-hH2L4V), The LCDR1 sequence is shown in SEQ ID NO: 81 (21F6C6-hH2L4V).
  • Biacore was used for affinity analysis, and CM5 chip immobilized anti-human Fc antibody was used to capture the test antibody, and the analyte was Siglec-15 protein. (The method is the same as in Example 6)
  • Table 6 shows the results of affinity analysis between the humanized antibody and Siglec-15 protein.
  • 21F6C6-mHL represents the chimeric antibody 21F6C6 composed of mouse anti-variable region and hIgG1 (174C11C9-mHL and 124B11F6-mHL and so on)
  • 21F6C6-hH1L1 represents the humanized designed huVH1 in Figure 4A and huVL1 in Figure 4B Humanized antibodies recombined with hIgG1 heavy chain constant region and Kappa light chain constant region respectively.
  • 124B11F6-hH1L1 represents the humanized antibody obtained by recombining the humanized designed huVH1 in Figure 4C and the huVL1 in Figure 4D with the hIgG1 constant region and the Lambda-C2 light chain constant region, respectively.
  • 174C11C9-hH2L2 represents the humanized antibody obtained by recombining the humanized designed huVH2 in Figure 4E and the huVL2 in Figure 4F with the hIgG1 constant region and the Kappa light chain constant region, respectively. Others and so on.
  • Example 11 Humanized antibodies can reverse Siglec-15-mediated inhibition of PBMC proliferation
  • PBMC peripheral blood mononuclear cells
  • serially diluted anti-Siglec-15 humanized antibody and hS15-hFc protein (1 ⁇ g/ml) were incubated at 37°C for 30 minutes, and 1 ⁇ 10 5 PBMC cells were added, and Soluble OKT3 (5ng/ml, eBioscience) was added to celltiterglo (Promega) after culturing for 3 days, and the fluorescence value was read to evaluate the cell proliferation.
  • Example 12 Anti-Siglec-15 humanized antibody can inhibit Siglec-15-mediated monocyte survival
  • mice SIGLEC15 humanized C57BL/6J mice (C57BL/6J-SIGLEC15HuGEMM), female, 6-8 weeks (the age of the mice at the time of tumor inoculation), and the body weight was 18-24 g (the body weight of the mice at the time of grouping) , a total of 50 mice (32 tumor-bearing mice were randomly selected according to the weight of mice and tumor size).
  • Mice were purchased from Shanghai Southern Model Animal Center (SMOC), animal certificate number: 20190002004257. Breeding environment: SPF grade.
  • Murine MC38-hSiglec15 cells (Clone#6, cell number ECL-00260) were cultured in DMEM medium containing 10% fetal bovine serum. MC38-hSiglec15 cells in exponential growth phase were collected for inoculation, resuspended in PBS, and subcutaneously inoculated at 5 ⁇ 10 6 cells/100 ⁇ L per mouse on the back right scapula. C57BL/6J-SIGLEC15HuGEMM mice were subcutaneously inoculated with MC38-hSiglec15 tumor cells to establish an allograft colon cancer cell tumor model.
  • the control group was the hIgG1 isotype control, and the treatment groups were 21F6C6-hH2L4V (10mg/kg), 174C11C9-hH2L2 (10mg/kg), 8 mice in each group; the control group and the administration group were all administered by intraperitoneal injection, according to the The tumor inhibition rate (TGI) was used to evaluate the efficacy.
  • TGI tumor inhibition rate
  • underlined sequences are HCDR1, HCDR2 and HCDR3, respectively, and the amino acid sequences are shown in SEQ ID NOs: 1, 3 and 5, respectively.
  • underlined sequences are HCDR1, HCDR2 and HCDR3, respectively, and the amino acid sequences are shown in SEQ ID NOs: 25, 26 and 29, respectively.
  • Data were collected in the experiment using the StudyDirectorTM (version number 3.1.399.19, supplier StudylogSystem, Inc., S. San Francisco, CA, USA) software, including the measurement of the long and short diameters of the tumor and the weighing of the animal body weight.
  • ⁇ T and ⁇ C are the mean tumor volume at a specific time point (MTV t ) in the treatment and control groups, respectively - the mean tumor volume at the time of grouping (MTV 1 )).
  • mice By analyzing the average tumor volume of mice on the 38th day after administration, the hIgG1 isotype (10mg/kg) control group mice had an average right tumor volume of 1134mm 3 on the 38th day after administration, and 21F6C6-hH2L4V (10mg/kg) treatment The tumor of the group began to disappear on the 6th day after administration, and all the mice were cured on the 13th day after the treatment, and the tumor volume of the 7 mice remained at 0mm 3 until the 38th day.
  • the inhibition rate TGI was 107%, which was statistically significant compared with the control group in anti-tumor effect (P ⁇ 0.005); the 174C11C9-hH2L2 (10mg/kg) treatment group started tumor on the 6th day after administration disappeared, all mice were cured on the 13th day after treatment, until the 38th day, the tumor volume of all mice was 0 mm 3 , and the tumor inhibition rate TGI was 108%, which had a statistically significant anti-tumor effect compared to the control group. Significant difference (P ⁇ 0.005).
  • the tumor growth in the control group and the treatment group is shown in Figure 7.
  • the body weight change curve of the control group and the treatment group with the treatment time is shown in Figure 8.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

一种抗Siglec-15抗体或其抗原结合片段、编码所述抗Siglec-15抗体或其抗原结合片段的核酸序列、包含该核酸序列的表达载体、包含该表达载体的宿主细胞、包含所述抗Siglec-15抗体或其抗原结合片段的组合物、双特异性抗体或所述抗Siglec-15抗体或其抗原结合片段与治疗剂连接的免疫连接物，以及所述Siglec-15抗体或其抗原结合片段在制备用于治疗癌症的药物中的用途。所述Siglec-15抗体或其抗原结合片段可与Siglec-15结合，用于治疗与Siglec-15相关的疾病。

Description

抗Siglec-15抗体及其在制备药物中的应用 技术领域
本发明涉及生物制药领域，具体涉及一种抗Siglec-15抗体或其抗原结合片段、编码本发明抗Siglec-15抗体或其抗原结合片段的核酸序列、包含该核酸序列的表达载体、包含该表达载体的宿主细胞、包含本发明抗Siglec-15抗体或其抗原结合片段的组合物、双特异性抗体或本发明抗Siglec-15抗体或其抗原结合片段与治疗剂连接的免疫连接物，以及本发明Siglec-15抗体或其抗原结合片段在制备治疗癌症的药物中的用途。
背景技术
癌症已成为危害人类健康的重要杀手。由于人口老龄化、工业化、城市化进程的加剧,生活方式的改变等原因,中国癌症的发病数和死亡数仍持续增加,癌症负担已不容忽视。癌症的发生发展是遗传和环境相互作用的结果,由正常组织中单一细胞基因突变恶性转化所造成的不受控的细胞增殖所引发。治疗癌症需在患者可承受的副作用下杀死或去除所有肿瘤细胞。随着手术，放化疗，靶向治疗等技术的发展，不少肿瘤患者的生存期有所延长，由于肿瘤的转移及其异质性，多数患者产生耐药或复发，并最终死亡。
近十年来，出现了以免疫检查点PD-1/PD-L1抑制剂为代表的一种新的免疫治疗方法，这些策略主要针对肿瘤免疫逃逸机制。当PD-1/PD-L1通路在肿瘤微环境中被激活时，效应T细胞的抗肿瘤免疫反应被抑制。阻断这一途径的治疗可有效改善多种肿瘤类型的抗肿瘤免疫反应。随着PD-1/PD-L1抗体药物的上市，肿瘤免疫治疗成为新兴的治疗范式，相较于放化疗与靶向治疗，PD-1/PD-L1抗体药物可使一部分病人获得长期缓解。免疫系统具有巨大的潜力，其能特异性识别并攻击肿瘤细胞而不对正常组织造成毒副作用。此外，免疫系统的记忆能力能防止肿瘤的复发。然而，PD-1/PD-L1抗体药物仅在20％-30％的患者中有效，如何使更多的患者从肿瘤免疫治疗中获益是目前急需解决的问题。这需要寻找新的免疫检查点治疗靶点进行药物开发。
唾液酸结合性免疫球蛋白样凝集素(sialic acid-binding immunoglobulin-like lectin，Siglec)家族是一类经典的免疫球蛋白样凝集素，可通过识别含有唾液酸的糖链结构，介导细胞与细胞或病原体间的相互作用，在固有免疫和适应性免疫中发挥重要的调控作用。目前已发现15种人源和9种鼠源的Siglec分子，Siglec特异性表达于髓系细胞和免疫细胞表面。Siglec家族蛋白为Ⅰ型跨膜蛋白，具有免疫球蛋白超家族结构域，不同的家族成员胞外部分有数量不等的“C2-set”免疫球蛋白样结构域，“C2-set”结构域与免疫球蛋 白恒定区具有很高的序列及折叠相似性。胞外末端免疫球蛋白结构域与抗体可变区具有较高的相似性，称为“V-set”结构域，另外还具有跨膜区和胞内段。大多数Siglec胞内段含有免疫受体酪氨酸抑制基序(immunoreceptor tyrosine-based inhibitiory motifs，ITIMs)，从而发挥免疫抑制功能。
Siglec-15为在进化中高度保守的Siglec家族成员，其胞外区有两个免疫球蛋白样结构域，“C2-set”结构域和“V-set”结构域，跨膜区包含一个与12kDa的信号衔接分子DNAX活化蛋白(DAP12)相互作用起到关键作用的赖氨酸残基(Lys274，人Siglec-15)，Siglec-15和DAP12的相互作用是通过跨膜区的离子键作用。DAP12具有非常短的胞外结构域(＜20个氨基酸)，跨膜区包含一个天冬氨酸残基(Asp50，人DAP12)，胞内区有一个ITAM(immunoreceptor tyrosine-based activating motif)，通过ITAM招募SYK使其磷酸化，以传递信号。
早期针对Siglec-15的研究主要集中在破骨细胞相关疾病领域。Hiruma等人报导了通过使用抗Siglec-15的多抗，抑制了RAW264.7小鼠巨噬细胞系(常作为破骨细胞前体模型)、小鼠骨髓巨噬细胞和人破骨细胞前体向破骨细胞的分化。Ishida-Kitagawa等人证明了Siglec-15与DAP12相互作用及SYK信号转导，以及Siglec-15与唾液酸化的配体的相互作用对破骨细胞分化是至关重要的。这些体外研究结果很快在转基因小鼠体内得到验证。Hiruma等人报导，Siglec15缺失小鼠表现出小梁骨轻度的骨硬化(增加的骨量)和尿脱氧吡啶啉(骨吸收的系统性标志)减少，表明破骨细胞活力降低。Takahata团队使用另外的Siglec15缺失小鼠品系也证明上述结果。
近期研究发现Siglec-15表达于肿瘤相关巨噬细胞上，由M-CSF(一种诱导巨噬细胞选择性活化/极化的细胞因子)诱导。共培养sialyl-Tn+肿瘤细胞株和M-CSF诱导的人巨噬细胞或Siglec-15+髓系细胞，提高了髓系细胞TGF-β(一种促进癌细胞上皮-间质转化和转移的多效细胞因子)的产生，其依赖于DAP12和SYK。这些结果表明Siglec-15可能在肿瘤微环境中具有重要的作用。
2019年3月5日，自然医学杂志刊登了陈列平教授团队的新发现：Siglec-15为肿瘤免疫微环境中新的免疫抑制检查点分子且可成为潜在的肿瘤免疫治疗靶点。研究发现，表达于肿瘤细胞或肿瘤相关巨噬细胞表面的Siglec-15能与T细胞表面受体相互作用，抑制T细胞肿瘤杀伤活性。Siglec-15能诱导单核细胞分化为特异性髓细胞，该类细胞抑制T细胞功能促进肿瘤生长。而更进一步进行体外实验发现敲除Siglec-15的小鼠的肿瘤生长降低，且使用Siglec-15单抗治疗后，可以抑制小鼠肿瘤生长。此外，PD-L1和Siglec-15的表达是互斥的，这就预示着Siglec-15的抗体有可能在抗PD-1/PD-L1免疫治疗无响 应的患者身上是有效的。以上结果提示Siglec-15是又一个在肿瘤微环境中参与免疫逃逸的分子，且有作为治疗靶标的潜力。
目前本领域对肿瘤疗法仍存在着未被满足的需求。
发明内容
为克服现有技术中缺乏治疗siglec-15相关疾病的药物的缺陷，本发明提供了抗Siglec-15抗体及其在制备药物中的应用。抗Siglec-15抗体与Siglec-15蛋白结合并表现出许多优良特性，包括例如与Siglec-15蛋白高亲和力结合。此外，本发明的抗体可逆转Siglec-15诱导的PBMC增殖抑制和抑制Siglec-15蛋白介导的单核细胞增殖，从而调控免疫应答。因此，本发明还涉及使用抗Siglec-15抗体或其抗原结合片段调控免疫应答的方法。本发明还提供了抗Siglec-15抗体或其抗原结合片段在制备治疗Siglec-15相关疾病的药物或制备治疗肿瘤的药物中的应用。
本发明的第一方面提供结合Siglec-15的分离的抗体及其抗原结合片段。在一些实施方案中，本发明抗Siglec-15抗体或其抗原结合片段包括选自以下组的一个或多个CDR(抗体互补决定区)序列：SEQ ID NO:1、2、3、4、5、6、7、8、9、10、11、12、13、14、15、16、17、18、19、20、21、22、23、24、25、26、27、28、29、30、31、32、33、34、35、36、37、38、39、40、81。
在另外的实施方案中，包括选自以下组的一个或多个重链CDR序列：SEQ ID NO:1、2、3、4、5、11、12、13、17、18、19、20、25、26、27、28、29、35、36、37，和/或，选自以下组的一个或多个轻链CDR序列：SEQ ID NO:6、7、8、9、10、14、15、16、21、22、23、24、30、31、32、33、34、38、39、40、81。
在一些实施方案中，本发明抗Siglec-15抗体或其抗原结合片段包括重链可变区，其包含HCDR1、HCDR2和HCDR3序列，和/或轻链可变区，其包含LCDR1、LCDR2和LCDR3序列，其中：
(a)所述重链可变区HCDR1序列包含选自SEQ ID NO:1、11、17、25、35及其保守修饰的氨基酸序列；所述重链可变区HCDR2序列包含选自SEQ ID NO:2、3、4、12、18、19、26、27、28、36及其保守修饰的氨基酸序列；所述重链可变区HCDR3序列包含选自SEQ ID NO:5、13、20、29、37及其保守修饰的氨基酸序列；
(b)所述轻链可变区LCDR1序列包含选自SEQ ID NO:6、7、14、21、30、31、38、81及其保守修饰的氨基酸序列；所述轻链可变区LCDR2序列包含选自SEQ ID NO:8、9、15、22、23、32、33、39及其保守修饰的氨基酸序列；所述轻链可变区LCDR3序列 包含选自SEQ ID NO:10、16、24、34、40及其保守修饰的氨基酸序列；
(c)所述抗体或其抗原结合片段与Siglec-15特异性结合。
在一个实施方案中，本发明提供结合Siglec-15的分离的抗体或其抗原结合片段，其包含重链可变区和/或轻链可变区，其中，重链可变区包括选自以下组的CDR序列：SEQ ID NO:1、2、3、4和5，轻链可变区包括选自以下组的CDR序列：SEQ ID NO:6、7、8、9、10和81。
在另一个实施方案中，本发明提供结合Siglec-15的分离的抗体或其抗原结合片段，其包含重链可变区和/或轻链可变区，其中，重链可变区包括选自以下组的CDR序列：SEQ ID NO:11、12和13，轻链可变区包括选自以下组的CDR序列：SEQ ID NO:14、15和16。
在另一个实施方案中，本发明提供结合Siglec-15的分离的抗体或其抗原结合片段，其包含重链可变区和/或轻链可变区，其中，重链可变区包括选自以下组的CDR序列：SEQ ID NO:17、18、19和20，轻链可变区包括选自以下组的CDR序列：SEQ ID NO:21、22、23和24。
在另一个实施方案中，本发明提供结合Siglec-15的分离的抗体或其抗原结合片段，其包含重链可变区和/或轻链可变区，其中，重链可变区包括选自以下组的CDR序列：SEQ ID NO:25、26、27、28和29，轻链可变区包括选自以下组的CDR序列：SEQ ID NO:30、31、32、33和34。
在另一个实施方案中，本发明提供结合Siglec-15的分离的抗体或其抗原结合片段，其包含重链可变区和/或轻链可变区，其中，重链可变区包括选自以下组的CDR序列：SEQ ID NO:35、36和37，轻链可变区包括选自以下组的CDR序列：SEQ ID NO:38、39和40。
在一个实施方案中，本发明提供结合Siglec-15的分离的抗体或其抗原结合片段，其包含重链可变区和/或轻链可变区，重链可变区包括HCDR1、HCDR2和HCDR3，轻链可变区包括LCDR1、LCDR2和LCDR3，其中，重链可变区HCDR1序列如SEQ ID NO:1所示，HCDR2序列选自SEQ ID NO:2、3和4，HCDR3序列如SEQ ID NO:5所示，轻链可变区LCDR1序列选自SEQ ID NO:6、7和81，LCDR2序列选自SEQ ID NO:8和9，LCDR3序列如SEQ ID NO:10所示。
在另一个实施方案中，本发明提供结合Siglec-15的分离的抗体或其抗原结合片段，其包含重链可变区和/或轻链可变区，重链可变区包括HCDR1、HCDR2和HCDR3，轻链可变区包括LCDR1、LCDR2和LCDR3，其中，重链可变区HCDR1序列如SEQ ID NO:11 所示，HCDR2序列如SEQ ID NO:12所示，HCDR3序列如SEQ ID NO:13所示，轻链可变区LCDR1序列如SEQ ID NO:14所示，LCDR2序列如SEQ ID NO:15所示，LCDR3序列如SEQ ID NO:16所示。
在另一个实施方案中，本发明提供结合Siglec-15的分离的抗体或其抗原结合片段，其包含重链可变区和/或轻链可变区，重链可变区包括HCDR1、HCDR2和HCDR3，轻链可变区包括LCDR1、LCDR2和LCDR3，其中，重链可变区HCDR1序列如SEQ ID NO:17所示，HCDR2序列选自SEQ ID NO:18和19所示，HCDR3序列如SEQ ID NO:20所示，轻链可变区LCDR1序列如SEQ ID NO:21所示，LCDR2序列选自SEQ ID NO:22和23，LCDR3序列如SEQ ID NO:24所示。
在另一个实施方案中，本发明提供结合Siglec-15的分离的抗体或其抗原结合片段，其包含重链可变区和/或轻链可变区，重链可变区包括HCDR1、HCDR2和HCDR3，轻链可变区包括LCDR1、LCDR2和LCDR3，其中，重链可变区HCDR1序列如SEQ ID NO:25所示，HCDR2序列选自SEQ ID NO:26、27和28，HCDR3序列如SEQ ID NO:29所示，轻链可变区LCDR1序列选自SEQ ID NO:30和31，LCDR2序列选自SEQ ID NO:32和33，LCDR3序列如SEQ ID NO:34所示。
在另一个实施方案中，本发明提供结合Siglec-15的分离的抗体或其抗原结合片段，其包含重链可变区和/或轻链可变区，重链可变区包括HCDR1、HCDR2和HCDR3，轻链可变区包括LCDR1、LCDR2和LCDR3，其中，重链可变区HCDR1序列如SEQ ID NO:35所示，HCDR2序列如SEQ ID NO:36所示，HCDR3序列如SEQ ID NO:37所示，轻链可变区LCDR1序列如SEQ ID NO:38所示，LCDR2序列如SEQ ID NO:39所示，LCDR3序列如SEQ ID NO:40所示。
本发明所述抗体或其抗原结合片段可为鼠源抗体、嵌合抗体、人源化抗体、全人源抗体或其片段，优选为全人源抗体、人源化抗体或其片段。
在一个实施方案中，本发明提供结合Siglec-15的分离的抗体或其抗原结合片段，其包含：重链可变区SEQ ID NO:41或其变体；和/或包含SEQ ID NO:42或其变体的轻链可变区。
在一个实施方案中，本发明提供结合Siglec-15的分离的抗体或其抗原结合片段，其包含：重链可变区SEQ ID NO:43或其变体；和/或包含SEQ ID NO:44或其变体的轻链可变区。
在一个实施方案中，本发明提供结合Siglec-15的分离的抗体或其抗原结合片段，其包含：重链可变区SEQ ID NO:45或其变体；和/或包含SEQ ID NO:46或其变体的轻链可 变区。
在一个实施方案中，本发明提供结合Siglec-15的分离的抗体或其抗原结合片段，其包含：重链可变区SEQ ID NO:47或其变体；和/或包含SEQ ID NO:48或其变体的轻链可变区。
在一个实施方案中，本发明提供结合Siglec-15的分离的抗体或其抗原结合片段，其包含：重链可变区SEQ ID NO:49或其变体；和/或包含SEQ ID NO:50或其变体的轻链可变区。
在一个实施方案中，本发明提供结合Siglec-15的分离的抗体或其抗原结合片段，其包含：包含具有与SEQ ID NO:41至少90％、95％、96％、97％、98％或99％同源性的氨基酸序列的重链可变区；和/或包含具有与SEQ ID NO:42至少90％、95％、96％、97％、98％或99％同源性的氨基酸序列的轻链可变区。
在一个实施方案中，本发明提供结合Siglec-15的分离的抗体或其抗原结合片段，其包含：包含具有与SEQ ID NO:43至少90％、95％、96％、97％、98％或99％同源性的氨基酸序列的重链可变区；和/或包含具有与SEQ ID NO:44至少90％、95％、96％、97％、98％或99％同源性的氨基酸序列的轻链可变区。
在一个实施方案中，本发明提供结合Siglec-15的分离的抗体或其抗原结合片段，其包含：包含具有与SEQ ID NO:45至少90％、95％、96％、97％、98％或99％同源性的氨基酸序列的重链可变区；和/或包含具有与SEQ ID NO:46至少90％、95％、96％、97％、98％或99％同源性的氨基酸序列的轻链可变区。
在一个实施方案中，本发明提供结合Siglec-15的分离的抗体或其抗原结合片段，其包含：包含具有与SEQ ID NO:47至少90％、95％、96％、97％、98％或99％同源性的氨基酸序列的重链可变区；和/或包含具有与SEQ ID NO:48至少90％、95％、96％、97％、98％或99％同源性的氨基酸序列的轻链可变区。
在一个实施方案中，本发明提供结合Siglec-15的分离的抗体或其抗原结合片段，其包含：包含具有与SEQ ID NO:49至少90％、95％、96％、97％、98％或99％同源性的氨基酸序列的重链可变区；和/或包含具有与SEQ ID NO:50至少90％、95％、96％、97％、98％或99％同源性的氨基酸序列的轻链可变区。
本发明的第二方面提供结合Siglec-15的分离的人源化抗体或其抗原结合片段，该人源化抗体包含在SEQ ID NO:41所示序列的选自以下的一个或多个位点处引入突变的重链可变区：M3、K19、S40、E42、R44、P61、T65、S77、T78、S84、S88、M93、V97、P117和/或S120位点，和/或在SEQ ID NO:42所示序列的选自以下的一个或多个位点处 引入突变的轻链可变区：V3、L4、A9、A12、V13、L15、Q17、A19、S22、K24、D32、Q46、P47、E59、I62、A64、N78、H80、P81、V82、E83、E84、A87、A104和/或L110。
在一个实施方案中，本发明提供结合Siglec-15的分离的人源化抗体或其抗原结合片段，其包含在SEQ ID NO:41所示序列的选自以下的一个或多个位点处引入突变的重链可变区：M3Q、K19R、S40A、E42G、R44G、P61A、T65K、S77N、T78S、S84N、S88A、M93V、V97A、P117Q和/或S120T，和/或，在SEQ ID NO:42所示序列的选自以下的一个或多个位点处引入突变的轻链可变区：V3Q、L4M、A9S、A12S、V13A、L15V、Q17D、A19V、S22T、K24R、D32E、Q46K、P47A、E59Q、I62V、A64S、N78T、H80S、P81S、V82L、E83Q、E84P、A87F、A104Q和/或L110I。
在一个实施方案中，本发明提供结合Siglec-15的分离的人源化抗体或其抗原结合片段，其包括重链可变区和/或轻链可变区，其中，重链可变区序列选自SEQ ID NO:51、53、55和57，轻链可变区选自SEQ ID NO:52、54、56、58和82。
在一个实施方案中，本发明提供结合Siglec-15的分离的人源化抗体或其抗原结合片段，该人源化抗体包括重链可变区和轻链可变区，其中，重链可变区序列包括SEQ ID NO:51所示序列或其变体，轻链可变区序列包括SEQ ID NO:52所示序列或其变体。
在一个实施方案中，本发明提供结合Siglec-15的分离的人源化抗体或其抗原结合片段，其包括重链可变区和轻链可变区，其中，重链可变区序列包括SEQ ID NO:53所示序列或其变体，轻链可变区序列包括SEQ ID NO:54所示序列或其变体。
在一个实施方案中，本发明提供结合Siglec-15的分离的人源化抗体或其抗原结合片段，其包括重链可变区和轻链可变区，其中，重链可变区序列包括SEQ ID NO:55所示序列或其变体，轻链可变区序列包括SEQ ID NO:56所示序列或其变体。
在一个实施方案中，本发明提供结合Siglec-15的分离的人源化抗体或其抗原结合片段，其包括重链可变区和轻链可变区，其中，重链可变区序列包括SEQ ID NO:57所示序列或其变体，轻链可变区序列包括SEQ ID NO:58所示序列或其变体。
在一个实施方案中，本发明提供结合Siglec-15的分离的人源化抗体或其抗原结合片段，其包括重链可变区和轻链可变区，其中，重链可变区序列包括SEQ ID NO:53所示序列或其变体，轻链可变区序列包括SEQ ID NO:56所示序列或其变体。
在一个实施方案中，本发明提供结合Siglec-15的分离的人源化抗体或其抗原结合片段，其包括重链可变区和轻链可变区，其中，重链可变区序列包括SEQ ID NO:53所示序列或其变体，轻链可变区序列包括SEQ ID NO:58所示序列或其变体。
在一个实施方案中，本发明提供结合Siglec-15的分离的人源化抗体或其抗原结合片 段，其包括重链可变区和轻链可变区，其中，重链可变区序列包括SEQ ID NO:53所示序列或其变体，轻链可变区序列包括SEQ ID NO:82所示序列或其变体。
本发明的第三方面提供结合Siglec-15的分离的人源化抗体或其抗原结合片段，其包含在SEQ ID NO:45所示序列的选自以下的一个或多个位点处引入突变的重链可变区：E1、Q5、L11、V12、R13、L20、T23、K38、R40、T41、E42、A61、P62、K67、A68、A72、S76、N77、L81、H82、T85、T87、V97和/或S113位点，和/或，在SEQ ID NO:46所示序列的选自以下的一个或多个位点处引入突变的轻链可变区：S8、F12、A18、Y36、L41、P43、K45、V47、T58、D74、G78、N81、I82、P84和/或V89位点。
在一个实施方案中，本发明提供结合Siglec-15的分离的人源化抗体或其抗原结合片段，其包含在SEQ ID NO:45所示序列的选自以下的一个或多个位点处引入突变的重链可变区：E1Q、Q5V、L11V、V12K、R13K、L20V、T23K、K38R、R40A、T41P、E42G、A61S、P62Q、K67R、A68V、A72R、S76T或S76A、N77S、L81M、H82E、T85S、T87R、V97A和/或S113T位点，和/或在SEQ ID NO:46所示序列的选自以下的一个或多个位点处引入突变的轻链可变区：S8P、F12A、A18V、Y36H、L41E、P43G、K45R、V47L、T58K、D74E、G78T、N81S、I82L、P84S和/或V89D位点。
在一个实施方案中，本发明提供结合Siglec-15的分离的人源化抗体或其抗原结合片段，其包括重链可变区和/或轻链可变区，其中，重链可变区序列选自SEQ ID NO:59、61、63和65，轻链可变区选自SEQ ID NO:60、62、64和66。
在一个实施方案中，本发明提供结合Siglec-15的分离的人源化抗体或其抗原结合片段，其包括重链可变区和轻链可变区，其中，重链可变区序列包括SEQ ID NO:59所示序列或其变体，轻链可变区序列包括SEQ ID NO:60所示序列或其变体。
在一个实施方案中，本发明提供结合Siglec-15的分离的人源化抗体或其抗原结合片段，其包括重链可变区和轻链可变区，其中，重链可变区序列包括SEQ ID NO:61所示序列或其变体，轻链可变区序列包括SEQ ID NO:62所示序列或其变体。
在一个实施方案中，本发明提供结合Siglec-15的分离的人源化抗体或其抗原结合片段，其包括重链可变区和轻链可变区，其中，重链可变区序列包括SEQ ID NO:63所示序列或其变体，轻链可变区序列包括SEQ ID NO:64所示序列或其变体。
本发明的第四方面提供结合Siglec-15的分离的人源化抗体或其抗原结合片段，其包含在SEQ ID NO:47所示序列的选自以下的一个或多个位点处引入突变的重链可变区：E1、Q5、P9、V10、L11、V12、M20、E23、K38、S40、K43、S44、N61、K67、A68、L70、V72、S76、N84、T87、S91和/或S119位点，和/或在SEQ ID NO:48所示序列的选 自以下的一个或多个位点处引入突变的轻链可变区：V3、L4、A9、A12、V13、L15、Q17、A19、S22、R43、R46、P47、E59、I62、A64、R72、D80、P81、V82、E83、A84、D85、V87、A104和/或L110位点。
在一个实施方案中，本发明提供结合Siglec-15的分离的人源化抗体或其抗原结合片段，其包含在SEQ ID NO:47所示序列的选自以下的一个或多个位点处引入突变的重链可变区：E1Q、Q5V、P9A、V10E、L11V、V12K、M20V、E23K、K38R、S40A、K43Q、S44G、N61A、K67R、A68V、L70M、V72R、S76T、N84S、T87R、S91T和/或S119T位点，和/或在SEQ ID NO:48所示序列的选自以下的一个或多个位点处引入突变的轻链可变区：V3Q、L4M、A9S、A12S、V13A、L15V、Q17D、A19V、S22T、R43K、R46K、P47A、E59Q、I62V、A64S、R72G、D80S、P81S、V82L、E83Q、A84P、D85E、V87F、A104Q和/或L110I位点。
在一个实施方案中，本发明提供结合Siglec-15的分离的人源化抗体或其抗原结合片段，其包括重链可变区和/或轻链可变区，其中，重链可变区序列选自SEQ ID NO:67、69、71和73，轻链可变区选自SEQ ID NO:68、70、72和74。
在一个实施方案中，本发明提供结合Siglec-15的分离的人源化抗体或其抗原结合片段，其包括重链可变区和轻链可变区，其中，重链可变区序列包括SEQ ID NO:67所示序列或其变体，轻链可变区序列包括SEQ ID NO:68所示序列或其变体。
在一个实施方案中，本发明提供结合Siglec-15的分离的人源化抗体或其抗原结合片段，其包括重链可变区和轻链可变区，其中，重链可变区序列包括SEQ ID NO:69所示序列或其变体，轻链可变区序列包括SEQ ID NO:70所示序列或其变体。
在一个实施方案中，本发明提供结合Siglec-15的分离的人源化抗体或其抗原结合片段，其包括重链可变区和轻链可变区，其中，重链可变区序列包括SEQ ID NO:71所示序列或其变体，轻链可变区序列包括SEQ ID NO:72所示序列或其变体。
在上述任何实施方案中，本发明抗体或其抗原结合片段的变体可包含一个、两个或三个保守修饰的氨基酸取代。
在上述任何实施方案中，本发明“大写英文字母+数字”表示该数字位置的氨基酸残基，“大写英文字母1+数字+大写英文字母2”，表示该数字位置的氨基酸残基由某一氨基酸替换为另一氨基酸残基，例如，“E1”代表氨基酸编号为1位置的氨基酸残基为谷氨酸，“E1Q”代表氨基酸编号为1位置的谷氨酸被替换为谷氨酰胺，“Q5”代表氨基酸编号为5位置的氨基酸残基为谷氨酰胺，“Q5V”代表氨基酸编号为5位置的谷氨酰胺被替换为缬氨酸，
在上述任何实施方案中，本发明抗体或其抗原结合片段可包含：人重链恒定区或其变体，其中所述变体包含至多20个保守修饰的氨基酸取代；和/或人轻链恒定区或其变体，其中所述变体包含至多20个保守修饰的氨基酸取代。在一些实施方案中，所述变体可包含至多10个保守修饰的氨基酸取代。在一些实施方案中，所述变体可包含至多5个保守修饰的氨基酸取代。在一些实施方案中，所述变体可包含至多3个保守修饰的氨基酸取代。在上述任何实施方案中，人重链恒定区或其变体可以是IgG1、IgG2、IgG3、IgG4、IgA、IgE、IgM或IgD恒定区或其变体，优选IgG1或IgG4恒定区或其变体。
本发明抗体或其抗原结合片段中氨基酸残基的编号方式为Kabat的EU索引的编号方式。
在上述任何实施方案中，本发明抗体或或其抗原结合片段可以以930pM或更低的KD结合Siglec-15。在另一个实施方案中，抗体或其抗原结合片段可以以614pM或更低的KD结合Siglec-15。在另一个实施方案中，抗体或其抗原结合片段可以以325pM或更低的KD结合Siglec-15。在另一个实施方案中，抗体或其抗原结合片段可以以202pM或更低的KD结合Siglec-15。在另一个实施方案中，抗体或其抗原结合片段可以以109pM或更低的KD结合Siglec-15。在另一个实施方案中，抗体或其抗原结合片段可以以85.6pM或更低的KD结合Siglec-15。在另一个实施方案中，抗体或其抗原结合片段可以以80.6pM或更低的KD结合Siglec-15。在另一个实施方案中，抗体或其抗原结合片段可以以72.4pM或更低的KD结合Siglec-15。在另一个实施方案中，抗体或其抗原结合片段可以以68.3pM或更低的KD结合Siglec-15。
可用任何有效的方法测量KD值。在优选的实施方案中，用生物发光干涉测量法(例如，实施例2中所述的ForteBio Octet法)来测量解离常数。在其它优选的实施方案中，可用表面等离子共振技术(例如Biacore)或Kinexa来测量解离常数。
在一些实施方案中，本发明抗体抗原结合片段包括但不限于为Fab、Fab’、F(ab’)2、Fv、或scFv、sdFv(disulfide-linked Fv)的抗体片段。
本发明中，Fab片段，由VL、VH、CL和CH1结构域组成的单价片段；F(ab’)2片段，包含通过铰链区二硫桥连接的两个Fab片段的二价片段；Fd片段，由VH和CH1结构域组成；Fv片段，由抗体单臂的VL和VH结构域组成；scFv片段，VL和VH区配对形成的单价分子。
在一些实施方案中，本发明抗Siglec-15抗体或其抗原结合片段可以与人Siglec-15结合。在另一些实施方案中，本发明抗Siglec-15抗体或其抗原结合片段可以与猴Siglec-15结合。在另一些实施方案中，本发明抗Siglec-15抗体或其抗原结合片段可以与鼠Siglec- 15结合。
在一些实施方案中，本发明抗Siglec-15抗体或其抗原结合片段与Siglec-15结合的表位相同或不同。
在一些实施方案中，本发明抗体片段为双特异性抗体。
本发明的第五方面还包括包含上述结合Siglec-15的抗体或其抗原结合片段中的任一种的双特异性抗体。
本发明的第六方面还包括编码本发明抗Siglec-15抗体及其抗原结合片段的核酸序列。
本发明的第七方面还包括包含编码本发明抗体或其抗原结合片段的核酸序列的表达载体。
本发明的第八方面还包括包含第七方面所述表达载体的宿主细胞。
此外，本发明的第九方面还包括制备本发明抗体或或其抗原结合片段的方法，该方法包括：(a)在使所述核酸序列表达的条件下在培养基中培养包含编码本发明抗体或其抗原结合片段的核酸的宿主细胞，由此产生包含轻链和重链可变区的多肽；和(b)从所述宿主细胞或培养基回收多肽。
本发明的第十方面还包括包含与可药用载体或稀释剂组合的本发明抗体或其抗原结合片段的组合物。
本发明的第十一方面还包括包含与治疗剂(例如细菌毒素或放射性毒素)连接的本发明抗Siglec-15抗体或其抗原结合片段的免疫连接物。细胞毒剂的非限制性实例包括：泰素(taxol)、细胞松弛素B(cytochalasin B)、丝裂霉素(mitomycin)、依托泊苷(etoposide)和长春新碱(vincristine)或其它抗代谢物、烷化剂、抗生素和抗有丝分裂药。本发明的第十二方面还包括本发明第一方面所述抗Siglec-15抗体或其抗原结合片段、第十方面所述的组合物、第十一方面所述的免疫连接物、第五方面所述的双特异性抗体在制备治疗Siglec-15相关疾病的药物中的应用。
或，本发明第一方面所述抗Siglec-15抗体或其抗原结合片段、第十方面所述的组合物、第十一方面所述的免疫连接物、第五方面所述的双特异性抗体用于治疗Siglec-15相关疾病。
或，一种治疗Siglec-15相关疾病的方法，其包括向有需要的受试者施用本发明第一方面所述抗Siglec-15抗体或其抗原结合片段、第十方面所述的组合物、第十一方面所述的免疫连接物或第五方面所述的双特异性抗体。
本发明所述Siglec-15相关疾病包括但不限于癌症或骨病相关疾病。所述癌症或骨病相关疾病可以是Siglec-15阳性癌症和骨病；
所述癌症包括但不限于白血病、黑色素瘤、头颈癌、胶质母细胞瘤细胞、乳腺癌、卵巢癌、胃癌、尿路上皮癌、胃食管癌、食道癌、子宫内膜癌、结肠癌、肝癌、肺癌或膀胱癌；其中所述白血病包括急性淋巴细胞性白血病(Acute lymphocytic leukemia，ALL)、急性骨髓性白血病(Acute myelogenous leukemia，AML)、慢性淋巴细胞性白血病(Chronic lymphocytic leukemia，CLL)、慢性骨髓性白血病(Chronic myelogenous leukemia，CML)；
所述骨病包括但不限于骨质疏松症、骨丢失、骨关节炎、骨软化症等。
本发明还包括本发明抗Siglec-15抗体或其抗原结合片段在用于制备逆转Siglec-15-hFc介导的PBMC增殖抑制药物中的用途。
本发明还包括本发明抗Siglec-15抗体或其抗原结合片段在用于制备抑制Siglec-15蛋白介导的单核细胞增殖的药物中的用途。
本发明还包括本发明抗Siglec-15抗体或其抗原结合片段在用于制备抑制Siglec-15蛋白介导的单核细胞存活的药物中的用途。
本发明还包括本发明抗Siglec-15抗体或其抗原结合片段在用于制备调控免疫应答的药物中的用途。
本发明的第十三方面还包括本发明第一方面所述抗Siglec-15抗体或其抗原结合片段、第十方面所述的组合物、第十一方面所述的免疫连接物、第五方面所述的双特异性抗体在制备抑制肿瘤细胞生长的药物中的用途。
或，本发明第一方面所述抗Siglec-15抗体或其抗原结合片段、第十方面所述的组合物、第十一方面所述的免疫连接物、第五方面所述的双特异性抗体用于抑制肿瘤细胞生长。
或，一种抑制肿瘤细胞生长的方法，其包括向有需要的受试者施用本发明第一方面所述抗Siglec-15抗体或其抗原结合片段、第十方面所述的组合物、第十一方面所述的免疫连接物或第五方面所述的双特异性抗体。
在一些实施方案中，抗Siglec-15抗体或其抗原结合片段可与第二治疗剂或治疗形式组合。
在一个实施方案中，用抗Siglec-15抗体或其抗原结合片段的治疗可与化疗组合。
在一个实施方案中，用抗Siglec-15抗体或其抗原结合片段治疗可与放疗组合。
在一些实施方案中，抗Siglec-15抗体或其抗原结合片段可与用于治疗癌症的另一种治疗性抗体联合。
本发明的积极进步效果在于：
本发明获得一种新的与Siglec-15具有高亲和力的抗体或抗原结合片段、其制备方法、 含其的组合物或免疫连接物或双特异性抗体，本发明获得抗Siglec-15抗体或其抗原结合片段具有调控免疫应答的方法，并且具有治疗肿瘤的作用。
附图说明
图1为抗Siglec-15嵌合抗体与293T-hu-S15的结合曲线以及EC50值。
图2A为嵌合抗体21F6C6对Siglec-15蛋白诱导的PBMC增殖抑制的逆转曲线图及EC50值。
图2B为嵌合抗体75E1F2对Siglec-15蛋白诱导的PBMC增殖抑制的逆转曲线图及EC50值。
图2C为嵌合抗体174C11C9对Siglec-15蛋白诱导的PBMC增殖抑制的逆转曲线图及EC50值。
图2D为嵌合抗体124B11F6对Siglec-15蛋白诱导的PBMC增殖抑制的逆转曲线图及EC50值。
图2E为嵌合抗体255C12B10对Siglec-15蛋白诱导的PBMC增殖抑制的逆转曲线图及EC50值。
图3为抗Siglec-15嵌合抗体抑制Siglec-15蛋白介导的单核细胞增殖。
图4A为21F6C6嵌合抗体重链可变区人源化设计图。
图4B为21F6C6嵌合抗体轻链可变区人源化设计图。
图4C为124B11F6嵌合抗体重链可变区人源化设计图。
图4D为124B11F6嵌合抗体轻链可变区人源化设计图。
图4E为174C11C9嵌合抗体重链可变区人源化设计图。
图4F为174C11C9嵌合抗体轻链可变区人源化设计图。
图5A为人源化抗体21F6C6-hH1L1、21F6C6-hH2L2逆转Siglec-15蛋白介导的PBMC增殖抑制的百分比曲线图以及EC50值。
图5B为人源化抗体21F6C6-hH2L3、21F6C6-hH3L3逆转Siglec-15蛋白介导的PBMC增殖抑制的百分比曲线图以及EC50值。
图5C为人源化抗体21F6C6-hH2L4、21F6C6-hH4L4逆转Siglec-15蛋白介导的PBMC增殖抑制的百分比曲线图以及EC50值。
图5D为人源化抗体124B11F6-hH1L1、124B11F6-hH2L2、124B11F6-hH3L3逆转Siglec-15蛋白介导的PBMC增殖抑制的百分比曲线图以及EC50值。
图5E为人源化抗体174C11C9-hH1L1、174C11C9-hH2L2、174C11C9-hH3L3逆转 Siglec-15蛋白介导的PBMC增殖抑制的百分比曲线图以及EC50值。
图6为抗Siglec-15人源化抗体抑制Siglec-15蛋白介导的单核细胞增殖图。
图7为MC38-hSiglec15肿瘤模型中对照组和治疗组小鼠肿瘤体积的生长曲线。
图8为MC38-hSiglec15肿瘤模型中对照组和治疗组随着治疗时间的体重变化曲线。
具体实施方式
下面通过实施例的方式进一步说明本发明，但并不因此将本发明限制在所述的实施例范围之中。下列实施例中未注明具体条件的实验方法，按照常规方法和条件，或按照商品说明书选择。
实施例1、Siglec-15抗原及检测用蛋白的制备
以UniProt Sialic acid-binding Ig-like lectin 15 Isoform 1的人Siglec-15胞外区域(F20-F263)作为模板，获得编码本发明抗原及检测用蛋白的基因序列，与抗体重链Fc片段(如人IgG1)或者His标签重组，经HEK293或者Expi293细胞表达纯化，获得本发明抗原及检测用蛋白，蛋白生产厂家为北京百普赛斯生物科技股份有限公司，货号分别为SG5-H5253(Fc标签)和SG5-H52H3(His标签)，其中人Siglec-15胞外区域序列如SEQ ID NO:75所示，其中1-19为氨基酸残基为信号肽序列，40-158位氨基酸残基为“V-set”结构域，168-251位氨基酸残基为“C2-set”结构域；人Siglec-15全长胞外区域与人IgG1Fc片段连接得到的重组蛋白(简称hS15-hFc)序列如SEQ ID NO:76所示，其中，1-244位氨基酸残基为Siglec-15全长胞外区域序列，253-483位氨基酸残基为人IgG1Fc序列；Siglec-15第一结构域(Domain 1，包含“V-set”结构域)与人IgG1Fc连接得到的重组蛋白(简称hS15-D1-hFc)序列如SEQ ID NO:77所示，其中1-4位氨基酸残基为信号肽序列，5-152位氨基酸残基为Siglec-15第一结构域(其中25-143位氨基酸残基为Siglec-15“V-set”结构域序列)，153-159位氨基酸残基为连接子(Linker)序列，160-390位氨基酸残基为人IgG1Fc序列；人Siglec-15全长胞外区域与His标签序列连接得到的蛋白序列如SEQ ID NO:78所示，其中1-244位氨基酸残基为人Siglec-15全长胞外区域序列，253-262位氨基酸残基为His标签序列。检测用小鼠和食蟹猴Siglec-15蛋白为商业化产品，购买自北京百普赛斯生物科技股份有限公司，货号分别为SG5-M52H7和SG5-C52H6。食蟹猴Siglec-15全长胞外区域与His标签序列连接得到的蛋白序列如SEQ ID NO:79所示，其中1-244位氨基酸残基为猴Siglec-15全长胞外区域序列，253-262位氨基酸残基为His标签序列。小鼠Siglec-15全长胞外区域与His标签序列连接得到的蛋白序列如SEQ ID NO:80所示，其中1-239位氨基酸残基为鼠Siglec-15全长胞外区域序列，248-257位氨基酸残基 为His标签序列。
实施例2、抗人Siglec-15杂交瘤单克隆抗体的制备
用经佐剂乳化的hS15-hFc免疫15只小鼠(5只C57bl/6,5只balb/c,5只SJL)，2周后用hS15-hFc或者hS15-D1-hFc免疫。取血清进行ELISA实验来评估抗血清滴度。选择血清滴度较高的小鼠进行脾细胞融合。最后一次加强免疫3天后取脾脏细胞进行融合，采用电融合的方式共进行5轮融合，每个融合后获得的杂交瘤细胞铺50块96孔板。对杂交瘤上清进行结合活性实验筛选出阳性克隆，并进一步进行亚克隆。通过结合活性实验和体外免疫细胞功能实验筛选出阳性克隆进行测序。
结果：通过结合活性实验和体外免疫细胞功能实验筛选得到5个阳性杂交瘤克隆，分别为21F6C6、75E1F2、124B11F6、174C11C9和255C12B10，5个杂交瘤克隆的重链可变区和轻链可变区序列分别如下所示。
21F6C6：
重链可变区序列(SEQ ID NO:41)：
Figure PCTCN2021128759-appb-000001
上述下划线序列分别为HCDR1、HCDR2和HCDR3，氨基酸序列分别如SEQ ID NO:1、2和5所示。SEQ ID NO:3和4均为在SEQ ID NO:2上进行了1或2个氨基酸替换获得。
轻链可变区序列(SEQ ID NO:42)：
Figure PCTCN2021128759-appb-000002
上述下划线序列分别为LCDR1、LCDR2和LCDR3，氨基酸序列分别如SEQ ID NO:6、8和10所示。SEQ ID NO:7和9分别为在SEQ ID NO:6和8上进行了1个氨基酸替换获得。
75E1F2：
重链可变区序列(SEQ ID NO:43)：
Figure PCTCN2021128759-appb-000003
上述下划线序列分别为HCDR1、HCDR2和HCDR3，氨基酸序列分别如SEQ ID NO:11、12和13所示。
轻链可变区序列(SEQ ID NO:44)：
Figure PCTCN2021128759-appb-000004
上述下划线序列分别LCDR1、LCDR2和LCDR3，氨基酸序列分别如SEQ ID NO:14、15和16所示。
124B11F6：
重链可变区序列(SEQ ID NO:45)：
Figure PCTCN2021128759-appb-000005
上述下划线序列分别为HCDR1、HCDR2和HCDR3，氨基酸序列分别如SEQ ID NO:17、18和20所示。SEQ ID NO:19为在SEQ ID NO:18上进行了2个氨基酸替换获得。
轻链可变区序列(SEQ ID NO:46)：
Figure PCTCN2021128759-appb-000006
上述下划线序列分别为LCDR1、LCDR2和LCDR3，氨基酸序列分别如SEQ ID NO:21、22和24所示。SEQ ID NO:23为在SEQ ID NO:22上进行了1个氨基酸替换获得。
174C11C9：
重链可变区序列(SEQ ID NO:47)：
Figure PCTCN2021128759-appb-000007
上述下划线序列分别为HCDR1、HCDR2和HCDR3，氨基酸序列分别如SEQ ID NO:25、26和29所示。SEQ ID NO:27和28均为在SEQ ID NO:26上进行了1或2个氨基酸替换获得。轻链可变区序列(SEQ ID NO:48)：
Figure PCTCN2021128759-appb-000008
上述下划线序列分别为LCDR1、LCDR2和LCDR3，氨基酸序列分别如SEQ ID NO:30、32和34所示。SEQ ID NO:31和33分别为在SEQ ID NO:30和32上进行了1个氨基酸替换获得。
255C12B10：
重链可变区序列(SEQ ID NO:49)：
Figure PCTCN2021128759-appb-000009
上述下划线序列分别为HCDR1、HCDR2和HCDR3，氨基酸序列分别如SEQ ID NO:35、36和37所示。
轻链可变区序列(SEQ ID NO:50)：
Figure PCTCN2021128759-appb-000010
上述下划线序列分别为LCDR1、LCDR2和LCDR3，氨基酸序列分别如SEQ ID NO:38、39和40所示。
注：上述序列中，下划线序列分别为重链可变区或轻链可变区的CDR1、CDR2和CDR3，被3个CDR序列隔开的依次为重链可变区或轻链可变区的4个框架区序列FWR1、FWR2、FWR3、FWR4。抗体具体的CDR序列及其编号如下表1所示。
表1 抗体的CDR序列信息
Figure PCTCN2021128759-appb-000011
Figure PCTCN2021128759-appb-000012
实施例3、抗人Siglec-15抗体与不同种属来源Siglec-15蛋白的结合
将杂交瘤筛选获得的抗体可变区与人IgG1(N297A)恒定区合成嵌合抗体，分别命名为21F6C6、75E1F2、124B11F6、174C11C9和255C12B10嵌合抗体。不同种属来源Siglec-15蛋白与嵌合抗体进行结合活性实验，人/小鼠/食蟹猴种属来源Siglec-15蛋白来源于北京百普赛斯生物科技股份有限公司。抗原包被0.5μg/ml，抗体从1μg/ml梯度稀释后与抗原进行孵育，二抗使用辣根过氧化物酶标记的Anti-Human IgG抗体，加入底物后读取OD 450值。
结果：5个抗Siglec-15嵌合抗体均与人Siglec-15和食蟹猴Siglec-15有结合活性，其中源于124B11F6、174C11C9和255C12B10杂交瘤的嵌合抗体与鼠Siglec-15有结合活性。表2所示为抗Siglec-15嵌合抗体与不同种属的Siglec-15抗原结合的EC 50值。
表2 抗Siglec-15嵌合抗体与不同种属的Siglec-15抗原结合的EC 50值
Figure PCTCN2021128759-appb-000013
Figure PCTCN2021128759-appb-000014
实施例4、抗人Siglec-15抗体与表达人Siglec-15的细胞的结合
过表达人Siglec-15的HEK293T细胞系购买自康源博创(HEK293T-hu-S15细胞系，货号KC-1314)，纯化的抗Siglec-15嵌合抗体以100nM梯度稀释与HEK293T-hu-S15细胞系4℃孵育30分钟，抗人IgG(Fc特异性)-FITC(货号：F9512)二抗添加到样品中孵育30分钟随后通过流式细胞术进行分析。
结果：5个抗Siglec-15嵌合抗体均与HEK293T-hu-S15细胞系结合。图1是抗Siglec-15嵌合抗体与HEK293T-hu-S15的结合曲线以及EC50值。
实施例5、重组抗体对Siglec-15蛋白亲和力评估
使用Biacore8K进行亲和力分析，CM5芯片固定抗人Fc抗体用来捕获待测抗体，将待测抗体原液样品稀释至5μg/mL，并以10μL/min的流速依次注入到实验通道约500RU。被分析物为Human Siglec-15,His Tag(Cat.No.SG5-H52H3)，将稀释后的人Siglec-15蛋白依次以30μL/min的流速注入到实验通道与参比通道，结合时间为150s，解离时间为700s。使用Biacore 8K分析软件计算每个抗体的KD值。
结果：表3是抗Siglec-15嵌合抗体与Siglec-15蛋白亲和力分析结果。
表3 抗Siglec-15嵌合抗体与Siglec-15蛋白亲和力分析结果
抗体名称 ka(1/Ms) kd(1/s) KD(M)
21F6C6嵌合抗体 3.95E+06 1.87E-04 4.73E-11
174C11C9嵌合抗体 1.21E+06 3.70E-04 3.05E-10
75E1F2嵌合抗体 8.41E+05 7.82E-04 9.30E-10
124B11F6嵌合抗体 1.02E+05 1.46E-07 1.43E-12
255C12B10嵌合抗体 2.96E+05 1.58E-04 5.36E-10
实施例6、嵌合抗体表位鉴定
使用Octet RED96e(ForteBio)仪器对待测抗体进行表位竞争实验。使用HIS1K生物传感器捕获Human Siglec-15,His Tag(Cat.No.SG5-H52H3)(5μg/mL)，与第一抗体(100nM)结合180s，在生物传感器上将Human Siglec-15,His Tag(抗原)-第一抗体与 第二抗体(100nM)结合90s，使用Octet RED96e(ForteBio)分析软件分析数据。
结果：表4是抗Siglec-15嵌合抗体互相竞争参数，60％-100％表示完全不竞争，表明抗原表位不一致或部分一致；20％-60％表示部分竞争，表明抗原表位部分一致；<20％表示完全竞争，表明抗原表位一致。
表4 抗Siglec-15嵌合抗体互相竞争参数
Figure PCTCN2021128759-appb-000015
注释：涂阴影单元格代表自反应对照结果。
实施例7、抗Siglec-15嵌合抗体可以逆转Siglec-15蛋白介导的PBMC增殖抑制
复苏冻存的外周血单核细胞(PBMC),梯度稀释抗Siglec-15嵌合抗体与hS15-hFc蛋白(0.5μg/ml)37℃孵育30分钟后，加入1×10 5个PBMC细胞，以及可溶的OKT3(0.5ng/ml，eBioscience)，培养3天后，加入celltiterglo(Promega)，读取荧光值来评价细胞增殖情况。
结果：5个抗Siglec-15嵌合抗体均可以逆转hS15-hFc介导的PBMC增殖抑制，图2A-E为抗体21F6C6、75E1F2、174C11C9、124B11F6和255C12B10回复抑制的百分比曲线图以及EC50值。
实施例8、抗Siglec-15嵌合抗体可以抑制Siglec-15蛋白介导的单核细胞存活
复苏从人PBMC中分离得到的冻存CD14+单核细胞，不同浓度的抗Siglec-15嵌合抗体和hS15-hFc蛋白37℃孵育30分钟后，加入1×10 5个CD14+单核细胞。培养6天后，向培养板中加入XTT(Roche，货号11465015001)，培养2小时后，读取OD450-OD690来测量细胞活力。
结果：图3所示hS15-hFc蛋白可以诱导CD14+单核细胞存活并增殖，抗Siglec-15嵌合抗体可以梯度抑制Siglec-15蛋白介导的单核细胞增殖。
实施例9、抗Siglec-15抗体人源化
将嵌合抗体21F6C6、124B11F6和174C11C9进行人源化设计，分别提供四条重链和四条轻链，见下表5。
表5 嵌合抗体的人源化设计
Figure PCTCN2021128759-appb-000016
结果：21F6C6人源化序列设计见图4A和图4B，124B11F6人源化序列设计见图4C和图4D，174C11C9人源化序列设计见图4E和图4F。其中灰色底纹部分是鼠源序列，加粗倾斜部分是CDR区序列，黑色底纹部分是人源化后序列，其余部分为原始人源序列。 图4A～4F中，人源化抗体的缩写“hu”与表5的“h”代表相同的意思，可以互换使用；以此类推到本发明中。
实施例10、人源化抗体对Siglec-15蛋白亲和力评估
对21F6C6、124B11F6和174C11C9人源化序列进行了不同组合表达(表6)。对21F6C6-hH2L4的LCDR1进行了点突变，获得人源化抗体21F6C6-hH2L4V，去除了异构化翻译后修饰位点，其轻链可变区序列为SEQ ID NO:82(21F6C6-hH2L4V)，LCDR1序列见SEQ ID NO:81(21F6C6-hH2L4V)。
使用Biacore进行亲和力分析，CM5芯片固定抗人Fc抗体用来捕获待测抗体，被分析物为Siglec-15蛋白。(方法同实施例6)
结果：表6是人源化抗体与Siglec-15蛋白亲和力分析结果。
表6 人源化抗体与Siglec-15蛋白亲和力分析结果
Figure PCTCN2021128759-appb-000017
其中，21F6C6-mHL代表鼠抗可变区与hIgG1构成的嵌合抗体21F6C6(174C11C9-mHL和124B11F6-mHL以此类推)，21F6C6-hH1L1代表图4A中人源化设计的huVH1 与图4B中huVL1分别与hIgG1重链恒定区以及Kappa轻链恒定区重组得到的人源化抗体。124B11F6-hH1L1代表图4C中人源化设计的huVH1与图4D中huVL1分别与hIgG1恒定区以及Lambda-C2轻链恒定区重组得到的人源化抗体。174C11C9-hH2L2代表图4E中人源化设计的huVH2与图4F中huVL2分别与hIgG1恒定区以及Kappa轻链恒定区重组得到的人源化抗体。其他以此类推。
实施例11、人源化抗体可以逆转Siglec-15介导的PBMC增殖抑制
复苏冻存的外周血单核细胞(PBMC)，梯度稀释抗Siglec-15人源化抗体与hS15-hFc蛋白(1μg/ml)37℃孵育30分钟后，加入1×10 5个PBMC细胞，以及可溶的OKT3(5ng/ml，eBioscience)，培养3天后，加入celltiterglo(Promega)，读取荧光值来评价细胞增殖情况。
结果：抗Siglec-15人源化抗体可以逆转hS15-hFc介导的PBMC增殖抑制，图5A-E为抗体回复抑制的百分比曲线图以及EC 50值。
实施例12、抗Siglec-15人源化抗体可以抑制Siglec-15介导的单核细胞存活
复苏从人PBMC中分离得到的冻存CD14+单核细胞，抗Siglec-15人源化抗体(10μg/ml)和hS15-hFc(2μg/ml)蛋白37℃孵育30分钟后，加入1×10 5个CD14+单核细胞。培养5天后，向培养板中加入celltiterglo(Promega)，读取荧光值来测量细胞活力。
结果：图6所示抗Siglec-15人源化抗体可以抑制Siglec-15蛋白介导的单核细胞增殖。
实施例13、抗Siglec-15人源化抗体在HuCELL肿瘤模型中的抗肿瘤药效评价
实验动物为SIGLEC15人源化的C57BL/6J小鼠(C57BL/6J-SIGLEC15HuGEMM)，雌性，6～8周(肿瘤接种时的小鼠周龄)，体重18-24g(分组时小鼠的体重)，共50只(根据小鼠体重和肿瘤大小各选择32只荷瘤鼠随机进行分组)。小鼠购自上海南方模式动物中心(SMOC)，动物合格证编号：20190002004257。饲养环境：SPF级。
鼠源MC38-hSiglec15细胞(Clone#6,细胞编号ECL-00260)培养在含有10％胎牛血清的DMEM培养基中。收集指数生长期的MC38-hSiglec15细胞用于接种，用PBS重悬细胞，每只小鼠按照5×10 6细胞/100μL在背部右侧肩胛处进行皮下接种。C57BL/6J-SIGLEC15HuGEMM小鼠皮下接种MC38-hSiglec15肿瘤细胞，建立同种移植结肠癌细胞肿瘤模型。对照组为hIgG1isotype同型对照，治疗组分别为21F6C6-hH2L4V(10mg/kg)，174C11C9-hH2L2(10mg/kg)，每组8只小鼠；对照组和给药组全部按照腹腔注射给药，根据肿瘤抑制率(TGI)进行疗效评价。
21F6C6-hH2L4V：
重链可变区序列(SEQ ID NO:53)：
Figure PCTCN2021128759-appb-000018
上述下划线序列分别为HCDR1、HCDR2和HCDR3，氨基酸序列分别如SEQ ID NO:1、3和5所示。
轻链可变区序列(SEQ ID NO:82)：
Figure PCTCN2021128759-appb-000019
上述下划线序列分别为LCDR1、LCDR2和LCDR3，氨基酸序列分别如SEQ ID NO:81、9和10所示。
174C11C9-hH2L2：
重链可变区序列(SEQ ID NO:69)：
Figure PCTCN2021128759-appb-000020
上述下划线序列分别为HCDR1、HCDR2和HCDR3，氨基酸序列分别如SEQ ID NO:25、26和29所示。
轻链可变区序列(SEQ ID NO:70)：
Figure PCTCN2021128759-appb-000021
上述下划线序列分别为LCDR1、LCDR2和LCDR3，氨基酸序列分别如SEQ ID NO:30、32和34所示。
肿瘤体积计算公式：肿瘤体积(mm 3)＝1/2×(a×b2)(其中a表示长径，b表示短径)。实验中使用StudyDirectorTM(版本号3.1.399.19，供应商StudylogSystem,Inc.,S.SanFrancisco,CA,USA)软件收集数据，包括肿瘤的长短径的测量和动物体重的称量。肿瘤抑制率，TGI(％)，计算公式如下：TGI％＝100×(1－ΔT/ΔC)。(ΔT和ΔC分别为治疗组和对照组在某一特定时间点的平均肿瘤体积(MTV t)－分组时的平均肿瘤体积(MTV 1))。
所有的统计分析和图形绘制都在R语言环境中进行(3.3.1版)。非特别说明的情况下，所有检验均为双尾检验，P值小于0.05时被认为具有统计显著性
实验结果：
通过对小鼠在给药后第38天肿瘤平均体积分析，hIgG1isotype(10mg/kg)对照组小鼠在给药后第38天右肿瘤平均体积为1134mm 3，21F6C6-hH2L4V(10mg/kg)治疗组在给药后第6天肿瘤开始消失，治疗后第13天所有小鼠被治愈，直到第38天7只小鼠肿瘤体积均一直保持为0mm 3，另有一只小鼠肿瘤复发，整体肿瘤抑制率TGI为107％，相较于对照组在抗肿瘤作用上具有统计学上的显著性差异(P＜0.005)；174C11C9-hH2L2(10mg/kg)治疗组在给药后第6天肿瘤开始消失，治疗后第13天所有小鼠被治愈，直到第38天所有小鼠肿瘤体积均为0mm 3，肿瘤抑制率TGI为108％，相较于对照组在抗肿瘤作用上具有统计学上的显著性差异(P<0.005)。对照组和治疗组肿瘤生长情况见图7。对照组和治疗组随着治疗时间的体重变化曲线见图8。本次研究结果表明，与阴性对照hIgG1isotype(10mg/kg)相比，21F6C6-hH2L4V(10mg/kg)和174C11C9-hH2L2(10mg/kg)单独治疗后在MC38-hSiglec15肿瘤模型上取得显著的抗肿瘤效果(P<0.005)，小鼠基本被治愈，肿瘤消失延长观察后，基本无肿瘤复发。

Claims (18)

  1. 一种结合Siglec-15的分离的抗体及其抗原结合片段，其特征在于，所述结合Siglec-15的分离的抗体或其抗原结合片段包括选自以下组的一个或多个CDR序列：SEQ ID NO:1、2、3、4、5、6、7、8、9、10、11、12、13、14、15、16、17、18、19、20、21、22、23、24、25、26、27、28、29、30、31、32、33、34、35、36、37、38、39、40、81；优选地，所述结合Siglec-15的分离的抗体或其抗原结合片段包括选自以下组的一个或多个重链CDR序列：SEQ ID NO:1、2、3、4、5、11、12、13、17、18、19、20、25、26、27、28、29、35、36、37，和/或，选自以下组的一个或多个轻链CDR序列：SEQ ID NO:6、7、8、9、10、14、15、16、21、22、23、24、30、31、32、33、34、38、39、40、81。
  2. 权利要求1所述的结合Siglec-15的分离的抗体或其抗原结合片段，其特征在于，所述结合Siglec-15的分离的抗体或其抗原结合片段包括重链可变区，其包含HCDR1、HCDR2和HCDR3序列，和/或轻链可变区，其包含LCDR1、LCDR2和LCDR3序列，其中：
    (a)所述重链可变区HCDR1序列包含选自SEQ ID NO:1、11、17、25、35及其保守修饰的氨基酸序列；所述重链可变区HCDR2序列包含选自SEQ ID NO:2、3、4、12、18、19、26、27、28、36及其保守修饰的氨基酸序列；所述重链可变区HCDR3序列包含选自SEQ ID NO:5、13、20、29、37及其保守修饰的氨基酸序列；
    (b)所述轻链可变区LCDR1序列包含选自SEQ ID NO:6、7、14、21、30、31、38、81及其保守修饰的氨基酸序列；所述轻链可变区LCDR2序列包含选自SEQ ID NO:8、9、15、22、23、32、33、39及其保守修饰的氨基酸序列；所述轻链可变区LCDR3序列包含选自SEQ ID NO:10、16、24、34、40及其保守修饰的氨基酸序列；或，
    (a)重链可变区包括选自以下组的CDR序列：SEQ ID NO:1、2、3、4和5，轻链可变区包括选自以下组的CDR序列：SEQ ID NO:6、7、8、9、10和81；或
    (b)重链可变区包括选自以下组的CDR序列：SEQ ID NO:11、12和13，轻链可变区包括选自以下组的CDR序列：SEQ ID NO:14、15和16；或
    (c)重链可变区包括选自以下组的CDR序列：SEQ ID NO:17、18、19和20，轻链可变区包括选自以下组的CDR序列：SEQ ID NO:21、22、23和24；或
    (d)重链可变区包括选自以下组的CDR序列：SEQ ID NO:25、26、27、28和29，轻链可变区包括选自以下组的CDR序列：SEQ ID NO:30、31、32、33和34；或
    (e)重链可变区包括选自以下组的CDR序列：SEQ ID NO:35、36和37，轻链可变区包括选自以下组的CDR序列：SEQ ID NO:38、39和40。
  3. 权利要求1所述的结合Siglec-15的分离的抗体及其抗原结合片段，其特征在于，所述结合Siglec-15的分离的抗体及其抗原结合片段包括重链可变区和/或轻链可变区，重链可变区包括HCDR1、HCDR2和HCDR3，轻链可变区包括LCDR1、LCDR2和LCDR3，其中，
    (a)重链可变区HCDR1序列如SEQ ID NO:1所示，HCDR2序列选自SEQ ID NO:2、3和4，HCDR3序列如SEQ ID NO:5所示，轻链可变区LCDR1序列选自SEQ ID NO:6、7和81，LCDR2序列选自SEQ ID NO:8和9，LCDR3序列如SEQ ID NO:10所示；或
    (b)重链可变区HCDR1序列如SEQ ID NO:11所示，HCDR2序列如SEQ ID NO:12所示，HCDR3序列如SEQ ID NO:13所示，轻链可变区LCDR1序列如SEQ ID NO:14所示，LCDR2序列如SEQ ID NO:15所示，LCDR3序列如SEQ ID NO:16所示；或
    (c)重链可变区HCDR1序列如SEQ ID NO:17所示，HCDR2序列选自SEQ ID NO:18和19所示，HCDR3序列如SEQ ID NO:20所示，轻链可变区LCDR1序列如SEQ ID NO:21所示，LCDR2序列选自SEQ ID NO:22和23，LCDR3序列如SEQ ID NO:24所示；或
    (d)重链可变区HCDR1序列如SEQ ID NO:25所示，HCDR2序列选自SEQ ID NO:26、27和28，HCDR3序列如SEQ ID NO:29所示，轻链可变区LCDR1序列选自SEQ ID NO:30和31，LCDR2序列选自SEQ ID NO:32和33，LCDR3序列如SEQ ID NO:34所示；或
    (e)重链可变区HCDR1序列如SEQ ID NO:35所示，HCDR2序列如SEQ ID NO:36所示，HCDR3序列如SEQ ID NO:37所示，轻链可变区LCDR1序列如SEQ ID NO:38所示，LCDR2序列如SEQ ID NO:39所示，LCDR3序列如SEQ ID NO:40所示。
  4. 权利要求1-3任一项所述的结合Siglec-15的分离的抗体及其抗原结合片段，其特征在于，所述结合Siglec-15的分离的抗体及其抗原结合片段可为鼠源抗体、嵌合抗体、人源化抗体、全人源抗体或其片段，优选为人源化抗体或其片段。
  5. 权利要求1所述的结合Siglec-15的分离的抗体及其抗原结合片段，其特征在于，所述结合Siglec-15的分离的抗体及其抗原结合片段包括：
    (a)重链可变区SEQ ID NO:41或与SEQ ID NO:41至少90％、95％、96％、97％、98％或99％同源性的氨基酸序列的重链可变区；和/或SEQ ID NO:42或与SEQ ID NO:42至少90％、95％、96％、97％、98％或99％同源性的氨基酸序列的重链可变区的轻链可变区；或
    (b)重链可变区SEQ ID NO:43或与SEQ ID NO:43至少90％、95％、96％、97％、 98％或99％同源性的氨基酸序列的重链可变区；和/或SEQ ID NO:44或与SEQ ID NO:44至少90％、95％、96％、97％、98％或99％同源性的氨基酸序列的重链可变区的轻链可变区；或
    (c)重链可变区SEQ ID NO:45或与SEQ ID NO:45至少90％、95％、96％、97％、98％或99％同源性的氨基酸序列的重链可变区；和/或SEQ ID NO:46或与SEQ ID NO:46至少90％、95％、96％、97％、98％或99％同源性的氨基酸序列的重链可变区的轻链可变区；或
    (d)重链可变区SEQ ID NO:47或与SEQ ID NO:47至少90％、95％、96％、97％、98％或99％同源性的氨基酸序列的重链可变区；和/或SEQ ID NO:48或与SEQ ID NO:48至少90％、95％、96％、97％、98％或99％同源性的氨基酸序列的重链可变区的轻链可变区；或
    (e)重链可变区SEQ ID NO:49或与SEQ ID NO:49至少90％、95％、96％、97％、98％或99％同源性的氨基酸序列的重链可变区；和/或SEQ ID NO:50或与SEQ ID NO:50至少90％、95％、96％、97％、98％或99％同源性的氨基酸序列的重链可变区的轻链可变区。
  6. 一种结合Siglec-15的分离的人源化抗体或其抗原结合片段，其包含在SEQ ID NO:41所示序列的选自以下的一个或多个位点处引入突变的重链可变区：M3、K19、S40、E42、R44、P61、T65、S77、T78、S84、S88、M93、V97、P117和/或S120位点，和/或，在SEQ ID NO:42所示序列的选自以下的一个或多个位点处引入突变的轻链可变区：V3、L4、A9、A12、V13、L15、Q17、A19、S22、K24、D32、Q46、P47、E59、I62、A64、N78、H80、P81、V82、E83、E84、A87、A104和/或L110；优选地，该人源化抗体或其抗原结合片段包含在SEQ ID NO:41所示序列的选自以下的一个或多个位点处引入下列突变的重链可变区：M3Q、K19R、S40A、E42G、R44G、P61A、T65K、S77N、T78S、S84N、S88A、M93V、V97A、P117Q和/或S120T，和/或，在SEQ ID NO:42所示序列的选自以下的一个或多个位点处引入下列突变的轻链可变区：V3Q、L4M、A9S、A12S、V13A、L15V、Q17D、A19V、S22T、K24R、D32E、Q46K、P47A、E59Q、I62V、A64S、N78T、H80S、P81S、V82L、E83Q、E84P、A87F、A104Q和/或L110I；更优选地，所述人源化抗体或其抗原结合片段包括重链可变区和/或轻链可变区，其中，重链可变区序列选自SEQ ID NO:51、53、55和57，轻链可变区选自SEQ ID NO:52、54、56、58和82；
    进一步更优选地，所述重链可变区如SEQ ID NO:51所示，和/或，所述轻链可变区如SEQ ID NO:52所示；或，所述重链可变区如SEQ ID NO:53所示，和/或，所述轻链可变区如SEQ ID NO:54所示；或，所述重链可变区如SEQ ID NO:53所示，和/或，所述轻 链可变区如SEQ ID NO:56所示；或，所述重链可变区如SEQ ID NO:53所示，和/或，所述轻链可变区如SEQ ID NO:58所示；或，所述重链可变区如SEQ ID NO:53所示，和/或，所述轻链可变区如SEQ ID NO:82所示；或，所述重链可变区如SEQ ID NO:55所示，和/或，所述轻链可变区如SEQ ID NO:56所示；或，所述重链可变区如SEQ ID NO:57所示，和/或，所述轻链可变区如SEQ ID NO:58所示。
  7. 一种结合Siglec-15的分离的人源化抗体或其抗原结合片段，所述人源化抗体或其抗原结合片段包含在SEQ ID NO:45所示序列的选自以下的一个或多个位点处引入突变的重链可变区：E1、Q5、L11、V12、R13、L20、T23、K38、R40、T41、E42、A61、P62、K67、A68、A72、S76、N77、L81、H82、T85、T87、V97和/或S113位点，和/或，在SEQ ID NO:46所示序列的选自以下的一个或多个位点处引入突变的轻链可变区：S8、F12、A18、Y36、L41、P43、K45、V47、T58、D74、G78、N81、I82、P84和/或V89位点；优选地，所述人源化抗体或其抗原结合片段包含在SEQ ID NO:45所示序列的选自以下的一个或多个位点处引入下列突变的重链可变区：E1Q、Q5V、L11V、V12K、R13K、L20V、T23K、K38R、R40A、T41P、E42G、A61S、P62Q、K67R、A68V、A72R、S76T或S76A、N77S、L81M、H82E、T85S、T87R、V97A和/或S113T位点，和/或，在SEQ ID NO:46所示序列的选自以下的一个或多个位点处引入下列突变的轻链可变区：S8P、F12A、A18V、Y36H、L41E、P43G、K45R、V47L、T58K、D74E、G78T、N81S、I82L、P84S和/或V89D；更优选地，所述结合Siglec-15的分离的人源化抗体或其抗原结合片段，包括重链可变区和/或轻链可变区，其中，重链可变区序列选自SEQ ID NO:59、61、63和65，轻链可变区选自SEQ ID NO:60、62、64和66；
    进一步优选地，所述重链可变区如SEQ ID NO:59所示，和/或，所述轻链可变区如SEQ ID NO:60所示；或，所述重链可变区如SEQ ID NO:61所示，和/或，所述轻链可变区如SEQ ID NO:62所示；或，所述重链可变区如SEQ ID NO:63所示，和/或，所述轻链可变区如SEQ ID NO:64所示。
  8. 一种结合Siglec-15的分离的人源化抗体或其抗原结合片段，其包含在SEQ ID NO:47所示序列的选自以下的一个或多个位点处引入突变的重链可变区：E1、Q5、P9、V10、L11、V12、M20、E23、K38、S40、K43、S44、N61、K67、A68、L70、V72、S76、N84、T87、S91和/或S119位点，和/或在SEQ ID NO:48所示序列的选自以下的一个或多个位点处引入突变的轻链可变区：V3、L4、A9、A12、V13、L15、Q17、A19、S22、R43、R46、P47、E59、I62、A64、R72、D80、P81、V82、E83、A84、D85、V87、A104和/或L110位点；优选地，所述人源化抗体或其抗原结合片段包含在SEQ ID NO:47所示 序列的选自以下的一个或多个位点处引入下列突变的重链可变区：E1Q、Q5V、P9A、V10E、L11V、V12K、M20V、E23K、K38R、S40A、K43Q、S44G、N61A、K67R、A68V、L70M、V72R、S76T、N84S、T87R、S91T和/或S119T位点，和/或在SEQ ID NO:48所示序列的选自以下的一个或多个位点处引入下列突变的轻链可变区：V3Q、L4M、A9S、A12S、V13A、L15V、Q17D、A19V、S22T、R43K、R46K、P47A、E59Q、I62V、A64S、R72G、D80S、P81S、V82L、E83Q、A84P、D85E、V87F、A104Q和/或L110I；更优选地，所述人源化抗体或其抗原结合片段包括重链可变区和/或轻链可变区，其中，重链可变区序列选自SEQ ID NO:67、69、71和73，轻链可变区选自SEQ ID NO:68、70、72和74；
    进一步更优选地，所述重链可变区如SEQ ID NO:67所示，和/或，所述轻链可变区如SEQ ID NO:68所示；或，所述重链可变区如SEQ ID NO:69所示，和/或，所述轻链可变区如SEQ ID NO:70所示；或，所述重链可变区如SEQ ID NO:71所示，和/或，所述轻链可变区如SEQ ID NO:72所示。
  9. 权利要求1-8任一项所述的结合Siglec-15的分离的抗体或其抗原结合片段，其特征在于，还包括恒定区或其变体，优选包括IgG1或IgG4恒定区或其变体。
  10. 编码权利要求1-9任一项所述的结合Siglec-15的分离的抗体及其抗原结合片段的核酸序列。
  11. 包含权利要求10所述的核酸序列的表达载体。
  12. 包含权利要求11所述的表达载体的宿主细胞。
  13. 制备权利要求1-9任一项所述的结合Siglec-15的分离的抗体或或其抗原结合片段的方法，该方法包括：
    (a)在使核酸序列表达的条件下在培养基中培养包含编码所述抗体或其抗原结合片段的核酸的宿主细胞，由此产生包含轻链和重链可变区的多肽；和
    (b)从所述宿主细胞或培养基回收多肽。
  14. 包含与可药用载体或稀释剂组合的权利要求1-9任一项所述的结合Siglec-15的分离的抗体或其抗原结合片段的组合物。
  15. 结合Siglec-15的分离的抗体或其抗原结合片段与治疗剂连接获得的免疫连接物。
  16. 包括权利要求1-9任一项所述的结合Siglec-15的分离的抗体或其抗原结合片段中的任一种的双特异性抗体。
  17. 权利要求1-9任一项所述的结合Siglec-15的分离的抗体或其抗原结合片段、权利要求14所述的组合物、权利要求15所述的免疫连接物、权利要求16所述的双特异性抗体在制备治疗Siglec-15相关疾病的药物中的应用；
    优选地，所述Siglec-15相关疾病包括但不限于癌症或骨病相关疾病。
  18. 权利要求1-9任一项所述的结合Siglec-15的分离的抗体或其抗原结合片段、权利要求14所述的组合物、权利要求15所述的免疫连接物、权利要求16所述的双特异性抗体在制备抑制肿瘤细胞生长的药物中的用途。
PCT/CN2021/128759 2020-11-05 2021-11-04 抗Siglec-15抗体及其在制备药物中的应用 Ceased WO2022095934A1 (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP21888626.5A EP4242231A4 (en) 2020-11-05 2021-11-04 ANTI-SIGLEC-15 ANTIBODY AND ITS USE IN THE PREPARATION OF A MEDICAMENT
US18/035,708 US20240092897A1 (en) 2020-11-05 2021-11-04 Anti-siglec-15 antibody and application thereof in preparing drug

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN202011221548 2020-11-05
CN202011221548.0 2020-11-05
CN202111095390.1 2021-09-17
CN202111095390 2021-09-17

Publications (1)

Publication Number Publication Date
WO2022095934A1 true WO2022095934A1 (zh) 2022-05-12

Family

ID=81362744

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2021/128759 Ceased WO2022095934A1 (zh) 2020-11-05 2021-11-04 抗Siglec-15抗体及其在制备药物中的应用

Country Status (4)

Country Link
US (1) US20240092897A1 (zh)
EP (1) EP4242231A4 (zh)
CN (1) CN114437216A (zh)
WO (1) WO2022095934A1 (zh)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117447595A (zh) * 2022-07-26 2024-01-26 北京东方百泰生物科技股份有限公司 一种抗Siglec-15单克隆抗体
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104321430A (zh) * 2012-03-30 2015-01-28 第一三共株式会社 新颖的抗-siglec-15抗体
CN104507969A (zh) * 2012-07-19 2015-04-08 阿莱斯亚生物疗法股份有限公司 抗siglec-15抗体
WO2016039402A1 (ja) * 2014-09-11 2016-03-17 塩野義製薬株式会社 血管内皮リパーゼの酵素活性を阻害するヒト化モノクローナル抗体
CN110035769A (zh) * 2016-09-21 2019-07-19 奈斯科尔公司 针对siglec-15的抗体及其使用方法
WO2020014306A1 (en) * 2018-07-10 2020-01-16 Immunogen, Inc. Met antibodies and immunoconjugates and uses thereof
CN111378043A (zh) * 2020-02-19 2020-07-07 南京医科大学 一种具有中和作用的人鼠嵌合抗Siglec-15全分子IgG及其制备方法和应用

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104321430A (zh) * 2012-03-30 2015-01-28 第一三共株式会社 新颖的抗-siglec-15抗体
CN104507969A (zh) * 2012-07-19 2015-04-08 阿莱斯亚生物疗法股份有限公司 抗siglec-15抗体
WO2016039402A1 (ja) * 2014-09-11 2016-03-17 塩野義製薬株式会社 血管内皮リパーゼの酵素活性を阻害するヒト化モノクローナル抗体
CN110035769A (zh) * 2016-09-21 2019-07-19 奈斯科尔公司 针对siglec-15的抗体及其使用方法
WO2020014306A1 (en) * 2018-07-10 2020-01-16 Immunogen, Inc. Met antibodies and immunoconjugates and uses thereof
CN111378043A (zh) * 2020-02-19 2020-07-07 南京医科大学 一种具有中和作用的人鼠嵌合抗Siglec-15全分子IgG及其制备方法和应用

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
NATURAL MEDICINE, 5 March 2019 (2019-03-05)
See also references of EP4242231A4
STUIBLE, M. ET AL.: "Mechanism and Function of Monoclonal Antibodies Targeting Siglec-15 for Therapeutic Inhibition of Osteoclastic Bone Resorption", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 289, no. 10, 7 March 2014 (2014-03-07), pages 6498 - 6512, XP055239659, DOI: 10.1074/jbc.M113.494542 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117447595A (zh) * 2022-07-26 2024-01-26 北京东方百泰生物科技股份有限公司 一种抗Siglec-15单克隆抗体
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
WO2024040195A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering

Also Published As

Publication number Publication date
CN114437216A (zh) 2022-05-06
EP4242231A1 (en) 2023-09-13
EP4242231A4 (en) 2024-10-23
US20240092897A1 (en) 2024-03-21

Similar Documents

Publication Publication Date Title
AU2019218319B2 (en) Anti-B7-H4 antibody, antigen-binding fragment thereof and pharmaceutical use thereof
US11525005B2 (en) Anti-CD40 antibody, antigen binding fragment thereof and medical use thereof
EP3744734A1 (en) Anti-4-1bb antibody, antigen-binding fragment thereof and medical use thereof
ES2737307T3 (es) Anticuerpos no antagonistas dirigidos contra la cadena alfa del dominio extracelular del receptor de IL7 y uso del mismo en el tratamiento del cáncer
CN116041530A (zh) 多特异性抗体及其制备和使用方法
WO2023001303A1 (zh) 药物组合物及用途
CN116323666A (zh) Fgfr3抗体和使用方法
IL304096A (en) Pd-1 binding molecule and application thereof
CN112243443B (zh) 抗trop-2抗体、其抗原结合片段及其医药用途
CA3180188A1 (en) Anti-flt3 antibodies and compositions
WO2023036281A1 (zh) 抗cd47抗体及其用途
WO2023104080A1 (zh) 抗trop-2抗体或其抗原结合片段
JP2020532279A (ja) 抗ｇｉｔｒ抗体、その抗原結合性断片、およびその医薬用途
WO2022095934A1 (zh) 抗Siglec-15抗体及其在制备药物中的应用
CN121079322A (zh) 抗cd27单克隆抗体及其应用
CA3160526A1 (en) Pharmaceutical combination and use thereof
HK40072607A (zh) 抗siglec-15抗体及其在制备药物中的应用
KR20260062948A (ko) Ctla4/tigit 결합 단백질 및 이의 의학적 용도
AU2026201066A1 (en) Anti-B7-H4 antibody, antigen-binding fragment thereof and pharmaceutical use thereof
HK40036076B (zh) 抗trop-2抗体、其抗原结合片段及其医药用途
CN119032103A (zh) 人源化和亲和力成熟的抗ceacam1抗体及使用方法
CN116234573A (zh) 抗trop-2抗体、其抗原结合片段或其突变体、及其医药用途
HK40048219A (zh) 靶向cd3的抗体、双特异性抗体及其用途
HK40048219B (zh) 靶向cd3的抗体、双特异性抗体及其用途
HK40012331B (zh) 抗b7-h4抗体、其抗原结合片段及其医药用途

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21888626

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2021888626

Country of ref document: EP

Effective date: 20230605